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14-3-3ζ is a ubiquitously expressed family member of proteins that have been 
implicated to have oncogenic potential through its interactions and involvement in cancer 
initiation and progression. 14-3-3ζ belongs to the highly conserved 14-3-3ζ protein family 
and modulates numerous pathways in cancer. Overexpression of 14-3-3ζ is an early 
event, occurs in more than 40% of human breast cancer cases, and is associated with 
disease recurrence and poor prognosis.  
Metabolic reprogramming is a hallmark of cancer. Cancer cells elevate aerobic 
glycolysis to produce metabolic intermediates and reducing equivalents, thereby 
facilitating cellular adaptation to the adverse environment and sustaining fast proliferation. 
Interestingly, new evidence has emerged that metabolic alteration may arise at early 
stages of breast cancer. However, little is known about what triggers metabolic 
reprogramming and how it mechanistically contributes to breast cancer initiation and 
progression. In this dissertation, I have characterized the functional role of 14-3-3ζ in 
metabolic alteration, cancer initiation and progression. The bioinformatic analyses of gene 
expression profiling from early-stages breast premalignant lesions showed that the 
expression of 14-3-3ζ is strongly correlated with the expressions of glycolytic genes, 
especially lactate dehydrogenase A (LDHA). Interestingly, this positive correlation was 
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also preserved in the advanced stage of breast cancer. Experimentally, my work 
demonstrated that increasing 14-3-3ζ expression in human non-transformed mammary 
epithelial cells (hMECs), MCF10A and MCF12A, transcriptionally up-regulated LDHA 
expression and increased glycolytic activity, which increased colony formation and 
promoted early transformation of hMECs. Conversely, knockdown of LDHA in these 14-
3-3ζ-overexpressing hMECs significantly decreased glycolytic activity and inhibited early 
transformation. Mechanistically, up-regulation of LDHA in 14-3-3ζ-overexpressing 
hMECs was directly mediated by the cAMP-response element-binding (CREB) 
transcription factor through 14-3-3ζ-mediated activation of the MEK-ERK signaling axis. 
Blocking MEK-ERK pathway in 14-3-3ζ-high expressing hMEC-derived 
MCF10DCIS.COM tumor lesions, significantly decreasing LDHA expression, reducing 
tumor cell proliferation, and effectively inhibiting tumor growth. Taken together, my studies 
demonstrate that 14-3-3ζ has pleiotropic functions on cancer metabolism dysregulation 
and tumorigenesis. While 14-3-3ζ has been identified as critical mediator in breast cancer 
initiation and early metabolic transformation, another key finding of this dissertation is that 
discovery of tumor cells selectively preserve high 14-3-3ζ expression during tumor 
progression process. 14-3-3ζ may involve in cell fitness mechanism that benefits cell 
survival and proliferation during cancer progression.  
Cancer is a sequential process of cell clone selection and competition. During cell 
competition; a “fit” clone population with better growth advantages outcompetes other 
subclones and eliminates “unfit” subclones. I found that 14-3-3ζ-low cells are eradicated 
by 14-3-3ζ-high cells when they grow together (HET tumors); however, 14-3-3ζ-low cells 
can still survive only when surrounded by cells with similar expression levels of 14-3-3ζ. 
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Mechanistically, 14-3-3ζ-low tumor cells produce a high level of cytokine macrophage 
inhibitory factor (MIF). Juxtacrine signaling involving MIF, its receptor CXCR2 and 
downstream production of interleukin-8 (IL-8), augmented cell proliferation and reduced 
cell apoptosis in 14-3-3ζ-high cells. Disruption of IL-8 or its upstream signaling, MIF or 
CXCR2, led to diminish cell fitness in 14-3-3ζ-high tumor cells and reduced tumor growth. 
Moreover, unlike conventional cell fitness, this study has revealed that 14-3-3ζ-high cells 
out-compete to sequester MIF, thereby causing cell death of 14-3-3ζ-low cells. I show 
that cancer cells may utilize part of immunity to trigger winner-loser cell interaction that 
determines the cell fate in solid tumors. Targeting the MIF-CXCR2-IL-8 axis could be an 
effective strategy to intervene in breast cancer progression. 
In summary, my work demonstrates that 14-3-3ζ has two distinct roles involving in 
cancer metabolism and cell competition, which may be developed into novel therapeutic 
strategies to target human breast cancer.  
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Chapter 1 
INTRODUCTION 
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1.1 Overview of Cancer 
1.1.1 Cancer Epidemiology and Statistics 
Cancer is the second leading cause of death in the United States, exceeded only 
by heart disease. In 2016, there is an overall estimation of about 1.68 million new cancer 
diagnoses, and it is estimated that about 595,000 of cancer deaths will occur in the U.S. 
(Figure 1) (1). The lifetime probability of developing an invasive cancer is about 42% in 
men and 38% in women. Interestingly, the cancer risk is higher for young women less 
than 50 years old (5.4%) than for young men (3.4%), due to relatively high incidences of 
breast, thyroid and genital cancer (1, 2). In 2016, the number of cancer survivors is the 
highest in American history with more than 15 million; in 2026, it is estimated that the 
number of cancer survivors will exceed 20 million in U.S. (Figure 2). The most prevalent 
cancers among males and females are prostate cancer and breast cancer, respectively 
(Figure 3) (2).  
Despite the continuously increasing cancer survival over the past two decades, 
cancer death rates are still high and continue to rise in the two most fatal cancers, 
pancreatic cancer and hepatic cancer. To overcome this trend requires collaboration in 
both laboratory and clinical efforts towards the better therapeutic strategy, control, and 
prevention of cancer (3, 4). Currently, based on the increasingly growing population in 
U.S., the annual direct medical costs for cancer, which was estimated at $124 billion in 
2011 (5), is expected to reach over $158 billion in 2020 (6). Recognition and advanced 
understanding of tumor biology will facilitate drug development for cancer treatment, 
improving clinical outcomes and ultimately leading to a significant increase of cancer 
survival rate.  
- 3 - 
 
 
 
 
Figure 1. Expected number of new cancer cases and deaths in United States in 
2016. In 2016, an estimated 841,390 new cases of cancer in males and 843,820 new 
cases in females will occur in United States. Reprinted with permission from Siegel RL, 
Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians 2016; 
66:7-30.  
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Figure 2. Expected number of cancer survivors in United States by 2016 and 2026. 
There is a fast growing number of cancer survivors. It is expected that there will be nearly 
21 million of cancer survivors in United States by 2026. Miller KD, Siegel RL, Lin CC; 
Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R; Ahmedin Jemal A. Cancer 
treatment and survivorship statistics, 2016 CA: A Cancer Journal for Clinicians 2016.  
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Figure 3. Trends in cancer incidence by sex in United States from 1975 to 2012. 
Prostate cancer and lung and bronchus caner are the most prevalent cancer in men; 
breast cancer and lung and bronchus caner are the most prevalent cancer in women. 
Reprinted with permission from Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. 
CA: A Cancer Journal for Clinicians 2016; 66:7-30. 
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1.1.2 Cancer Hallmarks 
Cancer is a term originally described by Greek physician, Hippocrates, who used 
it to illustrate the structure of veins on the external outside invasive surface of solid tumors . 
In the past century, researchers have been intensively investigating at the cancer genetic, 
molecular, cellular, and physiological levels, which has led us to a better understanding 
and categorization of the causes of cancer. Each tumor is a complex tissue containing 
diverse cell types that support each other and secure enough oxygen and nutrients to 
sustain tumor growth. Many lines of study discovered that tumorigenesis is caused by 
multiple steps such as DNA mutation and epigenetic alteration, which allow tumor cells 
to grow, survive and disseminate.  
A well-known review on the common features of cancer was put forth by Dr. 
Douglas Hanahan and Dr. Robert Weinberg, who enumerated the complexities of tumor 
biology and emerging knowledge of distinct cancer-associated mechanisms. Tumors are 
not only comprised of proliferating cells, instead involving diverse cell types able to 
interact with each other and even recruit cells from other organs to support their need for 
growth. Ten emerging cancer hallmarks describe eight acquired functional features and 
two empowering characteristics during carcinogenesis (Figure 4) (7, 8). These 
capabilities allow cancer cells to grow, proliferate, and disseminate to distant organs to 
form metastasis. Additionally, the acquired hallmarks are common features shared by 
almost all types of cancers, and those are: 1) sustaining proliferative signaling, 2) resisting 
apoptosis, 3) evading growth suppressors, 4) inducing angiogenesis, 5) enabling 
replicative immortality, 6) activating invasion and metastasis, 7) avoiding immune 
destruction, 8) dysregulating cellular energetic. Previous studies showed that acquisition 
- 7 - 
 
of cancer hallmarks requires two enabling characteristics, genome instability and tumor-
promoting inflammation, to increase genetic alteration in tumor cells, thereby fostering the 
development of incipient neoplasms into bulk tumor masses. In the following text, I will 
discuss several acquired capabilities of cancer hallmarks that are commonly shared by 
cancers. In-depth knowledge of tumor-promoting mechanisms will allow us to understand 
the biology of cancer in a comprehensive manners.   
                      
Figure 4. Ten emerging cancer hallmarks. There are ten characteristics and features 
that tightly link to cancer development. These capabilities allow cancer cells grow, survive, 
and disseminate to distant organs to form metastasis. Reprinted with permission from 
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-
674. 
Cancer 
Hallmarks 
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1.1.2.1 Sustaining proliferative signaling 
Normal cells require growth factor signals to control cell growth and proliferation. 
Growth signaling is transmitted in a spatially regulated fashion from a cell to its 
neighboring cells, thereby controlling total cell numbers and maintaining architecture of 
the tissues. It is still unclear how normal cells control the release of mitogenic signals; 
however, multiple studies have emerged showing how cancer cells are involving in 
mitogenic signaling and using it to gain advantage in tumor growth. Interestingly, unlike 
normal cells, cancer cells can provide growth factor ligands themselves, and use them to 
promote growth by receiving the signal through binding to cell-surface receptors that 
usually contain tyrosine kinase domain. This activates a signal cascade, and can result 
in unstoppable proliferation (9, 10). Monoclonal antibody inhibitors and small molecular 
inhibitors have been designed to block epidermal growth factor receptor (EGFR), a 
receptor tyrosine kinase, through distinct mechanisms that target either the extracellular 
ligand binding domain or cytoplasmic side of receptor, respectively. Cetuximab and 
panitumumab are examples of monoclonal antibody inhibitors; Gefitinib and Erlotinib 
represent small molecular inhibitors. Both classes of drugs are wildly used in the clinic. 
1.1.2.2 Resisting apoptosis 
Programmed cell death (PCD), plays a key role in tissue development and 
homeostasis (11), but can also occur when cells experience irreparable DNA damage or 
receive certain extracellular factors from the innate immune response to viral infection 
(12). Apoptosis is a type of PCD that is attenuated in tumors, commonly driven by a loss 
of TP53 tumor suppressor function. Alternatively, cancer cells can avoid apoptosis by 
upregulating protein expression of anti-apoptotic regulators such as Bcl-2, or reducing 
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expression levels of pro-apoptotic factors such as Bax, Bim, and Puma. Potential 
strategies to target cells that evade the apoptosis machinery are to use BH3 mimetic and 
other small molecules (13-16). The BH3 is a conserved domain shared by pro-apoptotic 
proteins such as Bim. The putative BH-3 mimetic, a small peptide inhibitor that mimics 
the BH3 domain, can bind to Bcl-2 pro-survival family members and initiate apoptosis (13, 
17). Studies of BH-3 mimetic, in particular ABT-737, showed a good clinical outcome 
through targeting Bcl-2, and thus inducing cell resensitization to apoptosis (16). However, 
optimization of therapy of BH3 treatment needs further study in the mechanism of BH3-
mediated apoptosis (18).  
1.1.2.3 Inducing angiogenesis  
Nutrients and oxygen are crucial to maintain tissue homeostasis and cell functions. 
Like all cells, tumor cells rely on blood vessels to obtain sufficient amounts of nutrients 
and oxygen while eliminating waste products to meet the demands for energy and 
proliferation. In 1971, Dr. Judah Folkman proposed that solid tumors are dependent on 
de novo angiogenesis to increase the supply of blood and nutrients (19). Following his 
hypothesis, he, together with Dr. Bert Vallee, soon identified fibroblast growth factor (FGF) 
as the first angiogenic factor, and began to deliver drugs attempting to target 
angiogenesis (20-22). Later in the 1980s, two other well-known angiogenic factors, 
vascular endothelial growth factor (VEGF) and angiogenin, were identified by other teams 
that had been inspired by Folkman’s work (23-25).  
During tumor development, angiogenesis may be stimulated by hypoxia or 
activated by vascular endothelial growth factor-A (VEGF-A) that is produced by tumor 
cells. Interestingly, VEGF can be further induced by low oxygen levels. Therefore, VEGF 
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signaling can be regulated at different levels, depending on its end purposes. VEGF can 
also be induced by proangiogenic signals such as fibroblast growth factor (FGF) to 
increase new vessel formation. Surprisingly, many studies reported that angiogenesis 
can occur in early neoplasms or non-invasive lesions, confirming that adequate nutrients 
and oxygen are critical factors for incipient neoplasms growth and survival. The 
development of anti-angiogenesis therapy showed promising results in inhibiting growth 
by reducing capillary buds to outgrow and spread into tumor masses. Bevacizumab, a 
first-line drug to inhibit growth of blood vessels, has shown promising results to prolong 
overall survival and reduce disease progression in many cancers and metastatic diseases 
(26-28).  
1.1.2.4 Enabling replicative immortality 
Telomerase, a terminal transferase that adds telomere repeat sequence the ends 
of 3’ telometric DNA, is expressed at a significant amount in immortalized cells such as 
cancer cells. Previous studies have shown that telomerases can protect the end of 
chromosomes, resulting in unlimited replicative potential and ultimately development into 
full-grown tumor (29). Telomerase functions to cause resistance to the induction of 
apoptosis and cellular senescence. In addition to cell senescence, some current studies 
show that telomerase is also involved in the regulation of cellular proliferation independent 
of its canonical function. This indicates that regulation of telomere maintenance and 
proliferation by telomerase are key requirement to fitness in terms of sustaining unlimited 
replicative potential and enabling replicative immortality. There are multiple inhibitors 
currently be developed for tackling telomerase, but they need further investigation in the 
field in order to translate into improved cancer prognoses (30). 
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1.1.2.5 Activating invasion and metastasis    
Metastasis is the leading cause of cancer death, and it affects millions of cancer 
patients (31, 32). Major neoplastic diseases such as breast cancer, colon cancer and 
melanoma have high incidences of metastasis (33, 34). Metastasis is extremely complex 
and dynamic, and generally presents as the advanced stage of cancer. Despite the 
continuous advances of modern medicine in better controlling disease, the circumstance 
of metastases steadily increases (35). Successful establishment and initiation of 
metastases requires a sequential process: cell invasion, migration, intravasation, 
transportation through blood vessels, extravasation, and colonization at secondary organ 
site (36). Epithelial-mesenchymal transition (EMT) plays an important role in promoting 
metastatic dissemination, and regulating cell invasiveness and migration in epithelium-
derived carcinoma (37, 38). Studies have shown that neoplastic cells that obtain invasive 
capability are able to transform cells into malignant cells. Pre-malignant cells that become 
invasive that are able to degrade the surrounding basement membrane (BM) through 
activating matrix degrading enzymes, extracellular matrix metalloproteases (MMPs), 
which reduce the barriers to migration, and dissemination and can ultimately result in a 
successful colonization (39).  
Unfortunately, there is no standard approach for targeting metastatic cancer. When 
patients are diagnosed with symptomatic metastases, the disease is likely too advanced 
to be controlled by any current treatments. Clearly, earlier detection/diagnosis combined 
with more effective treatments could provide better clinical management of metastasis to 
enhance the quality of life and prolong survival of patients (40). c-Met receptor tyrosine 
kinase/Hepatocyte growth factor (HGF) pathway has been shown to be involved in cell 
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migration and growth control in cancer development (41, 42). Additionally, c-Met is 
upregulated in many types of cancers and regulates cellular motility, migration and 
metastasis (43, 44). In preclinical models, knockdown of MET expression resulted in a 
decrease in cell invasion and migration, as well as impairing tumor growth and 
metastases in vivo. In addition to genetic approaches, crizotinib, a small molecule inhibitor 
that was developed to inhibit c-Met receptor phosphorylation, has been shown to 
successfully inhibit invasion and metastasis (40, 45, 46). Therefore, c-Met may be a 
potential drug target for treating metastasis (43, 47, 48).  
 
1.1.3 Overview of Cancer Metabolism 
Altered metabolism is one of the hallmarks of cancer (7, 49). Cancer cells are 
dependent on reprogramming multiple metabolic pathways, including carbohydrate 
metabolism, lipid metabolism, amino acid metabolism, to provide both energy and 
chemical building blocks for growth and proliferation (49-52).  
 
1.1.3.1 Warburg Effect and Glucose Metabolism 
The concept of metabolic dysregulation in cancer cells was first brought to light 
approximately ninety years ago by a physician scientist, Dr. Otto Warburg (53, 54). In the 
1920s, Dr. Otto Warburg found that tumor tissues have heavily increased glucose uptake 
and fermentation of glucose into lactic acid production, at the rate 10 times higher than 
normal tissues and even in the presence of oxygen; this observation is known as the 
Warburg effect (Figure 5) (55). In the 1950s, Warburg hypothesized that cancer cells have 
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an impaired capability for mitochondrial respiration, which results in unstoppable lactate 
production in the presence of oxygen (56). However, in fact, it was later reported that 
some cancer cells still maintain certain levels of oxidative phosphorylation (OXPHOS) 
and have a fully functioning mitochondria, even while displaying Warburg effect (57-61). 
Due to the phenomenon of an increase in glycolysis and lactate production while in the 
presence of oxygen, the Warburg effect is also named “aerobic glycolysis”.  
Why do cancer cells perform to aerobic glycolysis? Even today, the exact function 
of aerobic glycolysis is still controversial. Hypothetical explanations abound with one 
possible explanation being that cancer cells obtain a growth advantage through the 
Warburg effect (62, 63). They are six main functions of how the Warburg effect supports 
cell proliferation: 1) increases access to ATP by rapid ATP synthesis, 2) promotes flux 
into biosynthetic pathway, 3) enhances disruption of tissue architecture and tumor 
microenvironment, 4) allows for more reactive oxygen species (ROS) production, 5) 
modify chromatin structure, 6) alters immune function (Figure 6) (64).  
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Figure 5. Comparison between aerobic glycolysis (Warburg effect), oxidative 
phosphorylation (OXPHOS), and anaerobic glycolysis. Schematic representation of 
the difference in ATP production and biological flux under OXPHOS, fermentation, and 
aerobic glycolysis. Reprinted with permission from Vander Heiden MG, Cantley LC, 
Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell 
proliferation. Science 2009; 324:1029-1033.   
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Figure 6. Six proposed functions of Warburg effect. Cancer cells increase glucose 
uptake and lactate production to support rapid glycolysis. There are six proposed 
purposes of Warburg effect that have been wildly reported. ROS, reactive oxygen species. 
Modified and reprinted with permission from Liberti MV, Locasale JW. The Warburg Effect: 
How Does it Benefit Cancer Cells? Trends Biochem Sci 2016; 41:211-218. 
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Interestingly, the process of aerobic glycolysis only produces two ATPs at a time, 
which means that it does not efficiently utilize glucose to maximize ATP production (62). 
Instead, it generates biosynthetic building blocks to support rapid proliferation (64, 66). 
Although the Warburg effect in cancer cells is a relatively an inefficient way to generate 
ATP compared to the amount that is generated through OXPHOS in normal cells, it has 
been reported that in cancer cells 1) the glucose metabolism rate is 10-100 times that of 
normal cells, and 2) the total amount of ATP production is higher in cancer cells in a given 
time period. Therefore, the phenomenon of Warburg effect in cancer cells may due to 
competition for limited glucose and other nutrient resources to support high-energy 
demand for ATP synthesis in tumor microenvironment (67, 68). Notably, in addition to 
higher ATP production rate, the Warburg effect has been proposed to utilize glucose as 
a carbon source for anabolic process such as generation of lipids, proteins, ketone bodies, 
steroids, and nucleotides to maintain the high flux supply and keep the de novo 
biosynthesis pathway active. For instance, glycolysis can feed into the serine biosynthesis 
pathway that mediates production of nucleotides for cell division (69, 70).  
Interestingly, glucose metabolism also plays an important role to support T cell 
function and immune system. T cell activation requires a flux shift from OXPHOS into 
glycolysis via the regulation of mTOR pathway (71). Therefore, availability of glucose in 
tumor microenvironment may affect activity of tumor-infiltrating lymphocytes (TILs). 
Indeed, cancer cells can compete for the limited glucose with TILs in order to suppress 
the immune function in a living organism (72, 73). Rapid glycolysis in cancer cells could 
serve as a cell fitness mechanism to suppress T lymphocyte function and promote tumor 
growth. Moreover, lactate production allows cells to regenerate reducing equivalents of 
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NAD+, which recycles back into glycolysis and sustains active glycolysis (62, 65). 
Elevated aerobic glycolysis may result in a lower pH tumor microenvironment that affect 
tumor cells’ capabilities and change the immune system. For example, a decrease in pH 
in tumors by higher lactate triggers local cancer cell invasion (74). In addition, recent 
studies showed that tumor-derived lactic acid may contribute to M2 tumor-associated 
macrophage formation (TAM) (75). 
The Warburg effect may also cause an increase in generating reactive oxygen 
species (ROS) (76). Elevated glycolysis in cancer cells increases pentose phosphate 
pathway (PPP), leading to ROS production through NADPH oxidase (NOX). NOX is a 
critical enzyme to convert NADPH to ROS, which keeps active glycolysis by providing 
unlimited NADP+ (77). Maintaining the homoeostasis of superoxide is essential to keep 
mitochondria functions (78). Changes in redox potential contribute to oxidative stress that 
ultimately leads to damage in mitochondria and induces mutation of mitochondrial DNA 
(79-81). Multiple lines of studies have showed the link between mitochondrial dysfunction 
and cancer formation, implying that mutations in mitochondrial DNA (mtDNA) may result 
in mitochondrial dysfunction, thereby causing cancer initiation and progression (82). 
Taken together, these findings demonstrated the interplay between Warburg effect, ROS, 
and mitochondrial function in cancer. Both aerobic glycolysis and mitochondrial 
metabolism are essential for cell proliferation (64).  
In addition to the Warburg effect, several studies have addressed the link between 
glucose metabolism and histone acetylation (83). Histone acetylation, a critical element 
of gene regulation, is usually catalyzed by histone acetyltransferase (HAT). The amount 
of acetyl-coA in cells determines the level of histone acetylation through HAT, which may 
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impact tumor growth (84). The enzyme ATP-citrate lyase is primarily responsible for 
determining the synthesis of acetyl-coA, which is a precursor of thousands of metabolites 
that connects multiple cell signaling pathways (85, 86). Furthermore, knockdown of ATP-
citrate lyase decreased histone acetylation and changed global chromatin structure, 
thereby resulting in a reduction of expression of glucose-related enzymes (87). 
Additionally, acetyl-coA can serve as a substrate for protein lysine acetylation, which is a 
critical post-translational modification that affects enzymatic activity. Remarkably, almost 
every metabolic enzyme that catalyzes metabolic pathway can be acetylated (88). This 
implies that glucose metabolism has many effects on global epigenetic regulation, which 
in turn feeds back to regulate metabolism.  
Metabolic rewiring in cancer cells can be tightly linked to alteration of tumor-
associated genes. Tumor suppressor genes such as p53 and oncogenes like c-myc and 
HIF-1α were found to directly cause cancer, as well as being involved in reprogramming 
cancer metabolism (89-95). Recently, many lines of evidence showed that mutations in 
metabolic enzymes such as isocitrate dehydrogenase (IDH), succinate dehydrogenase 
(SDH), pyruvate kinase 2 (PKM2), and fumarate hydratase (FH) are sufficient to induce 
cancer initiation and progression (52). Importantly, mutations are also found in enzymes 
that have direct functions in mitochondrial metabolism (57), which implies that not only 
tumor-associated genes, but also mitochondrial-related genes can have pleiotropic 
functions on cancer metabolism dysregulation and tumorigenesis. 
One of the most famous metabolic genes that mediates carcinogenesis is 
embryonic isoform 2 of pyruvate kinase (PKM2). Cancer cells have been shown to 
express PKM2 to promote tumor growth by switching from mitochondrial oxidative 
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phosphorylation to glucose metabolism in order to generate ATP (96, 97). PKM2 
expression is necessary to drive aerobic glycolysis and confer advantages on tumor 
growth. The regulation of PKM2 activity is tightly controlled by metabolic master 
regulators such as hypoxia-inducible factor 1 (HIF-1). PKM2 can both be activated by, 
and activate HIF. Under hypoxia, knockdown of PKM2 reduces transcription of HIF1-
dependent target genes (96) and decreases glucose metabolism by inhibiting glycolytic 
gene expression in HeLa cells (98). However, PKM2 function in cells is controversial (85, 
99), as some studies have shown that inhibition of PKM2 may support tumor growth (100, 
101). These effects appear to be context-dependent and merit need further investigation. 
Interestingly, a PKM2 signature is also preserved in the failing human heart where 
decreases with mechanical unloading (102). 
1.1.3.2 Building Cells with Glucose and Glutamine 
It still remains elusive which comes first, alteration of cancer-associated genes or 
metabolism? In other words: are the oncometabolites always the cause or the 
consequence of increased cell proliferation? Due to the unique architecture of each tumor, 
it is always a “chicken and egg” situation. No matter which is the consequence or which 
is the cause, there is no doubt that cancer cells have common features of markedly 
utilizing glucose and glutamine as fuels to fulfill their demands for cell proliferation and 
survival. The catabolism of glucose and glutamine can generate pools of various carbon 
metabolites to use as building blocks to form thousands of macromolecules and maintain 
a complex metabolic network. In addition to the functions of glucose metabolism, 
glutamine uniquely provides nitrogen-containing intermediates for de novo nucleotide 
synthesis of purine and pyrimidine in cells (103-106). The increased glutamine uptake in 
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tumors was described by Dr. Harry Eagle, who found that HeLa cells consumed 10 times 
more glutamine than any other amino acid (107). Therefore, both glucose and glutamine 
are essential carbon sources for cancer cells (108). Furthermore, Craig Thompson and 
colleagues found that cancer cells can also use the hexosamine pathway to stimulate cell 
growth and rescue cells from cell death under glucose deprivation (109). The hexosamine 
biosynthesis leads to UDP-N-acetyl glucosamine (UDP-N-GlcNAc) synthesis and has 
been associated with posttranslational modification (PTM) via glycosylation. Under 
glucose deprivation, cells maintain hexosamine pathway which serves as a fuel signal to 
modulate growth factor receptor activity in a manner dependent on N-linked glycosylation. 
The activated hexosamine pathway sustains growth factor signaling, supports cell growth, 
and ultimately leads to stimulating glutamine uptake for cell growth and survival (109). 
A major question is: under nutrient-limiting conditions, how do tumor cells 
differentiate between available nutrients and selectively uptake one over others? Many 
studies have shown that influx of nutrients into tumor cells is not only stimulated to supply 
bioenergetics needs, but also by extracellular growth factors. Sustaining proliferative 
signaling is a hallmark of cancer (7). Therefore, when tumor cells are in a nutrient-
deprived situation, or the absence of growth factors, a compensatory signal can stimulate 
glucose transporter proteins (GLUTs) to traffic to the plasma membrane and activate 
glucose uptake (110-112). It is notable that hypoxic conditions can increase the rate of 
glucose uptake through activation of hypoxia-inducible factor 1 (HIF-1) (93, 113). Despite 
intensive studies to understand the mechanisms underlying specific metabolic alterations, 
it is now generally accepted that combinational therapy will be needed to tackle multiple 
targets of cancer metabolism due to the metabolic heterogeneity within tumors (114, 115).  
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1.1.4 Clonal Evolution and Tumor Heterogeneity 
Cancer is also considered an evolutionary process of cell clone selection and 
expansion (116, 117); over time, a clone population arises with comprehensive 
advantages that out-compete other tumor subclones for the limited space and resources 
within tumors (118). This clonal evolution theory was originated proposed by Dr. Peter 
Nowell, who hypothesized that cancer evolve from a single cell, and tumor progression 
acquired a sequential selection of competitive subpopulations that contains various 
genetic mutations, resulting in tumor growth (Figure 7) (116). Somatic mutations, 
epigenetic dysregulation, cellular context and microenvironmental stress all contribute to 
different levels of positive selection of clones for fitness, which results in intratumor 
heterogeneity and interpatient heterogeneity (118, 119). Advances in genome-scale 
approaches, such as next-generation sequencing analyses (NGS), enable the timely 
monitoring of clonal dynamics and assess regional heterogeneity directly in tumors (120, 
121). Recently, intratumor heterogeneity gained more attention because a patient can 
greatly benefit from genomic biomarker-guided therapy (122). Tumor heterogeneity 
explains the cellular complexity and dynamics that post challenges for current therapeutic 
strategies (123, 124). A full understanding of clonal evolution and dynamics of cell fitness 
may improve targeted therapy efficacy and may ultimately benefit personalized treatment 
medicine. 
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Figure 7. Schematic representation of tumor evolution. Cancer is a series processes 
of cell clone selection and expansion. As the tumor progresses, a sequential selection of 
competitive subpopulations with appearance of various morphological features. Somatic 
mutation is one of the proposed mechanism that contributes to intratumor phenotypic 
heterogeneity. Modified and reprinted with permission from 
http://www.cs.carleton.edu/faculty/loesper/research.html.   
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1.2 Breast cancer  
1.2.1 Breast Cancer Facts and Statistics  
After lung cancer, breast cancer is the most common cancer in women. According 
to the American Cancer Society, about 1 in 8 (12%) women in the United States will 
develop invasive breast cancer (IBC), and the chance that a woman will die from breast 
cancer is about 3% (1, 125-127). Moreover, breast cancer is also among the most 
common in female cancer survivors. In the United States, the annual estimation of newly 
diagnosed cases is about 236,660 for IBC cases; and 61,000 for ductal carcinoma in situ 
(DCIS) cases (128). Interestingly, 19% of breast cancer is diagnosed in women aged 30-
49 years, meaning that it develops earlier than other cancers such as lung and colorectal 
cancer. Although the death rate from breast cancer has significantly declined since 1989, 
the 5-year overall survival rate of breast cancer patients rapidly decreases from 100% for 
stage I disease to 22% for stage IV disease. Thus, there are unmet needs for prevention 
and early intervention (Table 1).  
1.2.2 Breast Cancer Initiation and Evolution  
Breast cancer is a genetically heterogeneous disease that contains multiple 
distinct cells, which contributes to diverse histological characteristics and different clinical 
outcomes (129, 130). In a simplified scenario, many breast cancers develop through 
multiple linear steps from normal epithelium, to ductal hyperplasia (DH), to atypical ductal 
hyperplasia (ADH or atypia), to ductal carcinoma in situ (DCIS), to invasive (infiltrating) 
ductal carcinoma (IDC), and finally, to metastatic breast cancer (Figure 8) (131-134). 
During disease progression, cells accumulate both genetic and non-genetic alterations 
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(135). However, it has been reported that metastatic cells may not necessarily go through 
a general mechanism of tumor development, but instead disseminate at the early stages 
of primary tumor development and grow in parallel with primary tumors (136, 137). The 
parallel metastasis theory implies that certain high fitness tumor clones with specific 
capabilities can disseminate into distant organs to form metastasis independent from the 
primary tumor. 
         
Figure 8. A linear progression model of ductal breast cancer development. In a 
simplified scenario, many breast cancers develop from normal epithelium, to pre-
malignant cells (ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma in 
situ), and to invasive ductal carcinoma. The bottom panel of IHC revealed the 
morphological structure of each stage of breast cancer. Modified and reprinted with 
permission from Moulis S, Sgroi DC. Re-evaluating early breast neoplasia. Breast Cancer 
Res 2008, 10: 302. And http://www.rnceus.com/dcis/sub.html. 
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Stage 5-year 
survival rate 
Symptom 
0 100% Stage 0 includes ductal hyperplasia (DH), atypical ductal 
hyperplasia (ADH or atypia), and ductal carcinoma in situ 
(DCIS). In DCIS, cancer cells are still within a duct and have 
not invaded deeper into the surrounding fatty breast tissue 
In all cases in stage 0, the cancer has not spread to lymph 
nodes or distant sites. 
I 100% The tumor is 2 cm or less across and has not no distant sites. 
The cancer hasn't spread to distant sites. 
II 93% The tumor is larger than 2 cm but less than 5 cm across. The 
cancer hasn't spread to distant sites. 
III 72% The tumor is any size and may or may not spread to lymph 
nodes. The cancer hasn't spread to distant sites. 
IV 22% The cancer can be any and may or may not have spread to 
nearby lymph nodes. It has spread to distant organs or to 
lymph nodes far from the breast. The most common sites of 
spread are the bones, liver, brain, or lungs. 
 
Table 1. Staging of breast cancer and 5-year survival rate. Breast cancer is staged 
base on pathologic features Table was modified and reprinted with permission from 
American cancer society. 
http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-staging.  
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Despite different routes of evolution and progression that breast cancer cells may 
take, there are stringent histopathological features that define the neoplastic stages and 
invasive stages of breast cancer (Figure 8). A normal breast duct contains a basement 
membrane and a bilayer of epithelial cells, in which luminal epithelial cells are surrounded 
by myoepithelial cells (130). In the DH and ADH pre-malignant breast diseases, the lumen 
is filled with non-invasive cells, which are considered as the precursor stage of DCIS. In 
DCIS lesions, proliferating cells are still confined within the basement membrane, 
showing no invasion into neighboring stroma cells and heterogeneously expressing basal 
cytokeratin markers (138). IDC may arise from DCIS (139), and the transition from DCIS 
to IDC is a critical trait of breast cancer progression. Loss of myoepithelial cells and 
basement membrane are characterized as the features of invasive breast cancer, in 
which cancer cells invade into the surrounding tissues and ultimately circulate to distant 
organs and forms metastases. 
 
1.2.3 Risk, Early Detection and Intervention 
Breast cancers initiate and develop through a series of stages of genetic and non-
genetic alteration. To reduce breast cancer death, it is critical to develop early prevention 
and detection approaches to interfere with breast cancer development at early stages. 
This requires better understanding mechanism of the critical mediators, driving early 
lesions (atypia) to progress to cancer and developing new interventions based on the 
understanding. 
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Based upon (1) molecular characteristics, (2) histological/clinical features of 
hormone receptor status of the human epidermal growth factor receptor 2 (HER2), 
estrogen receptor (ER), and progesterone receptor (PR), breast cancer can be grouped 
into different subtypes (Figure 9) (140-143). Current clinical treatment for breast cancer 
patients is dependent upon hormone receptor status. The basal-like/triple-negative (ER-, 
PR-, HER2-) BRAC1 mutation group has the worst prognosis and poor clinical outcome 
(144). 
 
 
 
Figure 9. Breast cancer subtypes. Based on gene expression profiles and clinical 
features, invasive breast cancer can be categorized into different subtypes include basal-
like, Her-2 enriched, luminal A, luminal B and normal-like breast cancer (140-143). 
Modified and reprinted with permission from McMaster Pathophysiology Review.  
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Because of the improvement in early detection and treatment, the overall 5-year 
relative cancer survival rate has greatly improved in breast cancer patients. Early 
detection has been aided by such advances such as mammography; the early 
interventions such as hormone therapy, chemotherapy, and targeted therapy have shown 
high efficacy in reducing breast cancer risk and continuously increasing the numbers of 
cancer survivors (2). Ultimately, the most effective way to reduce breast cancer mortality 
is prevention of early disease; however, progress in breast cancer prevention has been 
extremely limited with no true prevention options available at this time. Thus, there is an 
urgent need to identify the molecular alterations driving the initiation of breast cancer in 
order to rapidly test and develop targeted prevention strategies. Historically, progress has 
been limited by the inability to serially sample mammary cells from women who have pre-
malignant breast disease and prospectively test for predictors of cancer initiation and 
progression. Currently, there is a lack of biomarkers which would facilitate an early 
diagnosis. Therefore, it is important to find out the mechanism of cancer initiation and 
develop effective prevention strategies to win the battle with cancer. 
 
1.3 14-3-3 Proteins  
1.3.1 Overview of 14-3-3 proteins, structure, and functions 
The 14-3-3 proteins are a family of evolutionarily conserved molecules that are 
encoded by separate genes and expressed across all kinds of eukaryotic cells (145).The 
14-3-3 proteins are abundant in brain and neurons, and were originally described back in 
1967 by Dr. Moore and Dr. Perez (146). There are seven 14-3-3 isoforms in mammals: 
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β, γ, η, ζ, ε, σ, τ, and θ, which typically form homo and hetero-dimers with other isoforms 
to influence numerous signaling transduction events including the regulation of cell cycle, 
transcription, ion channels, intracellular trafficking, cytoskeleton rearrangement and 
apoptosis in cells (147-149).  
 
Through peptide library analyses, it was shown that proteins containing the 
consensus motifs, RSXpSXP or RXXXpSXP can be recognized by and directly interact 
with 14-3-3 proteins (150-152). Although 14-3-3 primarily binds to ligands with a 
phosphorylated motif, several experts have shown that there are some interactions 
between 14-3-3 and non-phosphorylated ligands as well (146, 152); these interactions 
can even show high affinity similar to those with phosphorylated proteins. However, most 
of the interactions between 14-3-3 and non-phosphorylated ligands can be out-competed 
and inhibited by phosphorylated ligands, leading to the notion 14-3-3 responds efficiently 
to signal transduction via heightened binding affinity to phosphorylated ligands. Besides 
targeting phosphorylated protein motifs, 14-3-3 proteins can be phosphorylated by 
kinases, which affect their ability to bind to target partners. Thus, many 14-3-3 cellular 
signaling cascades are tightly regulated by protein phosphorylation.  
 
Dimerized 14-3-3 is the predominant form to orchestrate signal transduction and 
cellular processes in cells (151). Crystal structures of 14-3-3 dimer have revealed that the 
14-3-3 protein can interact with two ligands concurrently with one ligand serving as a 
gatekeeper (Figure 10). Once the gatekeeper site is phosphorylated and binds to one of 
the monomers of the 14-3-3 dimer, it accelerates the secondary interaction between 
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another ligand and the second monomer (146, 147), thereby modulating protein function 
and subcellular localization. For example, Raf-1 has multiple 14-3-3 recognition motifs, 
and 14-3-3 dimer may bind to both affinity sites and induce a structural changes of Raf-
1, thereby regulating its activity. The binding of 14-3-3 dimer may also change the 
subcellular localization of a target protein by interfering with the nuclear localization 
sequence (NLS) on the target protein (153). The major proportion of 14-3-3 proteins are 
located in the cytoplasm; thus they might serve as cytoplasmic anchors that inhibit 14-3-
3 binding proteins from being translocated into the nucleus or promote the 14-3-3-bound 
complex exporting from the nucleus into the cytoplasm. The impact of 14-3-3-mediated 
subcellular localization of binding proteins could enormous to cellular functions and signal 
transduction cascades. For example, in neoplastic cells, 14-3-3 promotes YAP-1 
cytoplasmic localization via binding and retaining YAP-1 in the cytoplasm, thereby 
inhibiting YAP-1-mediated gene expression. (154).           
                                 
Figure 10. Crystal structure of dimerized 14-3-3 protein. Dimerized of 14-3-3 is critical 
for 14-3-3 function and activation. Software Pymol is used to make figure. PDB: 4E2E.   
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1.3.2 Role of 14-3-3 proteins in Cancer  
Dimerized 14-3-3 binds to many partners that drive diverse functions and control 
cell checkpoints. Accordingly, the biological functions of 14-3-3 are thought to highly be 
dependent on their binding proteins. In support of this notion, many studies have emerged 
in dissecting 14-3-3 binding partners (155, 156). Dr. Feng and colleagues showed by 
quantitative immunoprecipitation (IP) combined with a knockdown method (QUICK), more 
than 200 novel 14-3-3ζ binding substrates in multiple myeloma cells (155). Interestingly, 
this list included several metabolism-related pathways which had not been previously 
linked to 14-3-3 proteins. Their results strongly suggested that 14-3-3 participates in many 
of the networks in cell signaling pathways which may include cancer metabolism.  
Over the past two decades, 14-3-3 has gained the attention from the field due to 
its position at the center of signaling transduction. 14-3-3 proteins have hundreds of 
binding partners, which are involved in cell cycle control, nucleic acid synthesis and 
processing, cellular organization, storage and transportation, energy and metabolism, 
cellular communication, and signal transduction. Each individual isoform has distinct 
functions in cancer. For example, 14-3-3σ serves as tumor a suppressor. In contrast to 
14-3-3σ, 14-3-3ζ is a ubiquitously expressed family member that has been implicated to 
have oncogenic potential through its interactions and involvement in cancer initiation and 
progression. Through TCGA dataset (RNAseq) analyses, 14-3-3ζ (YWHAZ) 
overexpression has been observed across different cancer types (Figure 11). 
Interestingly, only a few mutations were found in 14-3-3ζ protein (Figure 11). However, 
14-3-3ζ (YWHAZ) overexpression was observed in > 40% of breast cancer and 
neuroendocrine prostate cancer, and part of overexpression was contributed by gene 
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amplification (Figure 12). Additionally, 14-3-3ζ (YWHAZ) overexpression occurs in > 10% 
tumors in more than fifteen different cancers.  
 
 
 
Figure 11. 14-3-3ζ (YWHAZ) overexpression across different cancer types. 14-3-3ζ 
overexpression has been observed across different cancer types. TCGA Data eBioPortal 
(http://www.cbioportal.org/) is the tool for data analysis. Each dot represents a patient 
sample. Blue dot: no mutation; red dot: missense: black triangle: frameshift; red triangle 
splicing; grey dot: not sequenced.  
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Figure 12. Alteration frequency of 14-3-3ζ (YWHAZ) across different cancer types. 
The most frequent alteration for 14-3-3ζ overexpression is gene amplification which has 
been observed in 126 patients across different cancer types. Data analysis is using TCGA 
Data eBioPortal (http://www.cbioportal.org/). Red columns indicate gene amplification; 
green columns indicate gene mutation; blue columns indicate gene deletion; grey 
columns indicate multiple alterations.  
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1.3.2.1 14-3-3ζ and Cancer  
14-3-3ζ belongs to the highly conserved 14-3-3 protein family and modulates 
numerous pathways in cancer (157). A heritable increase in 14-3-3ζ expression in cancer 
is associated with a poor prognosis and disease recurrence (158). As I discussed in the 
following chapters, in pre-malignant cells, 14-3-3ζ overexpression induces glycolysis 
through upregulation of LDHA (159), binds to metabolic proteins, which include fructose-
2,6,-bisphosphate kinase promoting metabolic functions (160), leads to Akt 
phosphorylation by activation of the PI3K pathway (161), destabilizes the p53/Smads 
complex by binding to YAP-1 (154), and triggers epithelial-to-mesenchymal transition, 
which may increase the transition of ductal carcinoma in situ (DCIS) to invasive breast 
cancer (162). In cancers, 14-3-3ζ overexpression enhances MAPK/c-Jun signaling (163) 
and regulates tumor immune response by modulation of expression of multiple cytokines 
(164, 165). Interestingly, quite a number of 14-3-3ζ-mediated cellular networks appear 
reported to be involved in cancer metabolism and cell competition, such as the Hippo 
pathway, the JNK pathway and the PI3K-Akt pathway (166). Moreover, 14-3-3ζ has 
distinct functions in regulating treatment resistance. Knockdown of 14-3-3ζ sensitizes 
cells to UV-induced apoptosis, which is mediated by the JNK/p38 signaling (145). Taken 
together, cancer cells with high 14-3-3ζ expression tend to promote cancer initiation and 
progression. 
 
1.4 Gap in Knowledge and Hypothesis  
After cardiovascular diseases, cancer is the second leading cause of death in the 
United States (1). Growing tumor cells must find alternative metabolic mechanisms to 
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take advantage of the limited nutrient resources provided by the body. Metabolic 
dysregulation has been recognized as a distinct hallmark of tumorigenesis and cancer 
progression.  
14-3-3ζ binds to and regulates phosphorylated proteins involved in numerous 
important cellular processes, including those essential for metabolic regulation, signaling 
transduction, and apoptosis. 14-3-3ζ overexpression is known to occur at the early 
neoplastic stage (ADH and DCIS) of breast disease and is found in >40% of invasive 
breast cancer patients. Remarkably, 14-3-3ζ overexpression persists throughout breast 
cancer progression (167).  
Additionally, as many reports showed that metabolic alteration is an early event in 
pre-malignant cells, I hypothesized that 14-3-3ζ overexpression in neoplastic cells may 
rewire metabolism and induce cancer initiation. In this dissertation, I therefore sought to 
investigate the role of 14-3-3ζ in metabolic alterations that may impact breast cancer 
initiation and progression (Chapter 2). Meanwhile, many lines of evidence exists 
reporting that cancer cells always grow in environments with limited nutrient resources 
and must compete fiercely to win the race of tumor formation and progression (116-118). 
Pathological gain of 14-3-3ζ function may confer advantages on cancer progressing in a 
heterogeneous tumor environment with individual cancer cells competing for limited 
resources. The level of 14-3-3ζ may determine the outcome of the competitive race for 
nutrients in primary tumor formation and progression. Therefore, I hypothesized that 14-
3-3ζ is a critical molecular mediator to secure limited nutrient resources among 
heterogeneous tumor cell populations. Consequently, I investigated the pathological 
function of 14-3-3ζ in breast cancer progression in vivo in Chapter 3. 
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Effective breast cancer prevention cannot be accomplished without combining 
knowledge from multiple disciplines. Metabolic alteration and tumor heterogeneity are two 
distinct cancer hallmarks, and 14-3-3ζ seems to be a key regulator directly involved in 
these two hallmarks. By comprehensively examining the characteristics of 14-3-3ζ in both 
preclinical models and clinical human samples, the results I obtained will lead to the 
discovery of new and better biomarkers for prognostic values and will further guide us to 
develop a novel therapeutic strategy for breast cancer that overexpresses 14-3-3ζ.   
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Chapter 2 
14-3-3ζ–MEDIATED LDHA UPREGULATION FACILIATES 
BREAST CANCER INITIATION AND PROGRESSION 
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2.1 Introduction  
2.1.1 Metabolic dysregulation and cancer initiation  
 
Breast cancers initiate and develop through a series of stages from normal cells to 
ductal hyperplasia (DH), to atypical ductal hyperplasia (ADH), to ductal carcinoma in situ 
(DCIS), to invasive (infiltrating) ductal carcinoma (IDC), and finally, to metastatic breast 
cancers (131). About 20% of the breast cancer patients present ADH and/or DCIS early-
stage breast disease in the clinic (158). Although advances in targeted therapies have 
shown efficacy to increase breast cancer survival rates (168), a better understanding of 
mechanisms underlying cancer initiation will allow us to improve early detection and 
intervention, which may further lead to a reduction of mortality from breast cancer. 
 
Breast cancer initiation and progression involve cascades of genetic and non-
genetic alterations, including metabolic perturbation (51, 169, 170). Recently, multiple 
lines of evidence have reported that metabolic reprogramming may occur at an early 
stage of neoplasia and contribute to cancer initiation and malignant transformation (103, 
171, 172). The Warburg effect is a phenomenon of an increase in glycolysis and lactate 
production while in the presence of oxygen, which promotes flux into the biosynthetic 
pathway to support cell proliferation (62). By examination of blood flow entering and 
leaving tumor lesions, Dr. Otto Warburg made the seminal discovery that cancer cells 
mainly exhibit a high rate of glycolysis. Major regulators of the Warburg effect include 
tumor suppressor genes, such as p53 and oncogenes like c-MYC and HIF-1α (173), 
which were found to directly cause cancer, as well as being involved in rewiring cancer 
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metabolism. These genes are critical because they can have pleiotropic functions on 
cancer metabolism alteration and tumorigenesis. However, it still remains elusive what 
other mediators may involve in mediating aerobic glycolysis at the early-stage of breast 
cancer. 
 
2.1.2 The role of LDHA in cancer metabolism 
 
Lactate dehydrogenase A (LDHA) is a critical enzyme that metabolizes the final 
step of glycolysis to generate lactate and provide enough NAD+ to support rapid 
proliferation of cancer cells (174, 175). Interestingly, lactate can be further used as a fuel 
for mitochondria functions and biosynthesis pathway in cancer cells (176). Elevated levels 
of LDHA are a cancer hallmark that is tightly associated with poor prognosis and critically 
involved in the tumor progression (177-180). LDHA has been reported as a key enzyme 
for highly glycolytic phenotype in many types of cancer (174, 181) and has gradually been 
considered as a high-priority target for cancer drug therapy. Several LDHA inhibitors have 
been developed (181), and Gossypol (AT-101) is one of the noncompetitive inhibitors 
binding to the lactate dehydrogenase isoenzyme that is being tested in multiple clinical 
trials (181-183). Selective LDHA inhibitor FX-11 can suppress the enzymatic function in 
vivo that blocks the conversion of pyruvate to lactate (184) and inhibits tumor growth both 
in vitro and in vivo (175). These inhibitors are promising to target LDHA; a further 
mechanistic understanding of the interplay between glucose metabolism and 
tumorigenesis can lead to optimize the efficacy of these agents in cancer treatment. 
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2.1.3 14-3-3ζ and cancer metabolism 
 
14-3-3ζ is a key protein that critically involves in numerous signal transduction and 
tumorigenesis (154, 185). In the past two decades, multiple high-throughput proteomic 
screenings have identified that 14-3-3ζ-targeted partners massively participate in various 
biological function, especially in the modulation of cellular metabolism (155, 186-190). 
These potential binding targets including enzymes that are in the center of glycolysis such 
as pyruvate kinase (PK), glyceraldehyde-3-phosphate dehydrogenase (GADPH) and 6-
phosphofructo-2-kinase (PFK-2) (191). AMP-activated protein kinase (AMPK), a master 
sensor in metabolic checkpoint, responds to cellular energy stress and mediates 
homeostasis. In cancer cells, 14-3-3ζ physically interacts with phosphorylated liver kinase 
B1 (LKB1, or STK11) (192) and suppresses binding and activation of its substrate AMPK, 
suggesting that 14-3-3ζ could be an important mediator of cellular metabolism. 
 
2.1.4 Hypothesis  
 
14-3-3ζ overexpression is an early event in human breast cancer, taking place as 
early as during the atypical ductal hyperplasia (ADH) (158, 167). Recent evidence 
suggests that metabolic alternation may occur at an early stage of neoplasia and 
contribute to cancer metabolic transformation (103, 171). Given the known roles that 14-
3-3ζ mediates numerous mechanisms in the early stage of breast epithelial cells and its 
probable involvement in metabolic alteration, I therefore hypothesized that pathological 
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14-3-3ζ overexpression in breast epithelial cells may trigger metabolism rewiring and 
contribute to the initiation of cancer. 
 
Briefly, in this chapter, I examined gene expression profiling data on three 
datasets: 1) a microarray dataset (GSE16873) generated from histologically normal 
epithelia, 2) RNAseq-derived Cancer Genome Atlas (TCGA), and 3) the microarray-
derived breast cancer dataset GSE2109 (193, 194). The bioinformatic analysis revealed 
that the expression of 14-3-3ζ is positively correlated with a number of genes in the 
glycolysis pathway, especially LDHA. Therefore, I sought to determine whether 14-3-3ζ 
modulates cellular glycolysis and metabolic flux in breast cancer. I identified a direct 
mechanistic link between 14-3-3ζ overexpression and LDHA upregulation, and showed 
that 14-3-3ζ-mediated LDHA upregulation is critical to early transformation of human 
mammary epithelial cells (hMECs). These data provide a direct evidence that 14-3-3ζ 
overexpression in early-stage breast cancer contributes to the metabolic dysregulation of 
breast epithelial cells. Importantly, I also demonstrate that targeting 14-3-3ζ could be an 
efficacious strategy for clinical intervention of early-stage breast cancer for the prevention 
of further disease progression.  
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2.2 Materials and Methods  
2.2.1 Cell lines and cell culture  
 
MCF10A and MCF12A cells were obtained from American type cell collection 
(ATCC) and were maintained in human mammary epithelial cells (hMECs) medium (154). 
MCF10DCIS.COM cells, provided by Dr. Fariba Behbod (195), were maintained in 
DMEM/F-12 media (#DFL13-500, Caisson,USA) supplemented with 5% horse serum 
(Gibco). All cell lines were authenticated and validated by MD Anderson Cancer Center’s 
Characterized Cell Line Core.  
 
2.2.2 Plasmids and shRNAs  
 
MCF10A, MCF12A and MCF10DCIS.COM cell lines were transfected with 
pcDNA3-HA-14-3-3ζ or pcDNA3 empty vector (Thermo Fisher Scientific, USA), which 
were constructed by Lu et al. (162), and selected with neomycin for 14-3-3ζ-
overexpressing sublines. 14-3-3ζ shRNA (clone, NM_003406.2-418s1c1) and LDHA 
shRNA (NM_005566) were used to make 14-3-3ζ and LDHA knockdown cell lines. 
 
2.2.3. Bioinformatics 
 
Glycolysis-related genes were extracted from the Gene Ontology database under 
the term "glycolytic process" (accession #GO: 0006096). The corresponding patient-
derived gene expression values were retrieved from the Gene Expression Omnibus data 
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repository microarray datasets for early-stage breast neoplasia (GSE16873) and 
advanced breast cancers (GSE2109), as well as the The Cancer Genome Atlas (TCGA) 
breast cancer datasets (http://cancergenome.nih.gov/). The clustering analysis of gene 
expression and heatmap visualization of the correlation matrix were performed in the 
corrplot package (v0.73) on the statistical computation software R (v3.1.2, https://www.r-
project.org/). Breast cancer patient-derived gene expression dataset GSE3494 had 
clinical follow-up information and was used to investigate the relationship between 14-3-
3ζ and/or LDHA expression and patient prognosis. Patients were stratified as having 
either "low" or "high" expression of the gene by median expression values of 14-3-3ζ and 
LDHA in the data cohort, respectively. Patients with "low" or "high" expression of both 14-
3-3ζ and LDHA genes were further extracted to investigate whether there is synergistic 
predictive effect to combine the two biomarkers together. The Kaplan-Meier plots and 
survival analysis of breast cancer patients (GSE3494) were performed using R package 
survival (v2.38). 
 
2.2.4 Real-time PCR analyses 
 
Total RNA was extracted with Trizol reagent (Thermo Fisher Scientific) following 
manufacturer’s protocol. LDHA, CREB, MYC mRNA expression were determined by the 
qRT-PCR using TaqMan primers (Hs00855332_g1, Hs00231713_m1 and 
Hs00153408_m1) and normalized to 18S rRNA endogenous control (#4310893E).  
 
2.2.5 Metabolic assays 
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For glucose uptake assays, cells (2x105) were plated in 6-well plate with DMEM 
/F12 media (#DFL13-500, Caisson,USA) supplemented 10% fetal bovine serum (Gibco) 
with for 24 hours before starting experiments. Then cells were replaced with DMEM/F-12 
media for 3 hours in order to cause a starving condition before 2-deoxy-D-glucose-[1,2-
3H(N)] (Moravek Biochemicals) was added in. The stock of 2-deoxy-D-glucose-[1,2-3H(N)] 
contains tritium with specific activity for 1 millicurie. 1μl 2-deoxy-D-glucose-[1,2-3H(N)] 
was added into 6-well plate for 1 hour. Therefore, each experiment contains 1 microcurie 
trillium signal. The cells were then trypsinized, and tritium signal was measured by liquid 
scintillation counting. For lactate production assay, cells were plated for 24 hours, 
followed by fresh-medium incubation for 1 hour. Lactate production was measured 
according to the manufacturer’s instructions (BioVision Inc). For oxygen consumption 
assays, cells (2x105) were plated in a 96-well oxygen biosensor system (BD Biosciences) 
covered with mineral oil to prevent oxygen leakage. according to the manufacturer’s 
instructions (196). The signals (Ex/Em: 485/630 nm) were read using a Synergy 2 
microplate reader (BioTek, Winooski) immediately after cell plating (baseline) and 1 hour 
after plating. The oxygen consumption rate was calculated and normalized to baseline. 
The overall cellular glycolytic activity was evaluated as previously described by Xu et al. 
(197). 
 
2.2.6 Soft agar colony formation assay 
Colony formation assay was analyzed by plating 0.5% top agar (BD, New Jersey) 
that contained cells (2x105) with medium into 6-well plates coated with 1% agar. Cells 
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were maintained with the addition of fresh medium twice weekly. The average culture 
timing depends on the tumorigenicity of the cells which is typically three to five weeks. 
The cells were then stained with 0.005% crystal violet, and the cell colonies were counted 
manually. This assay was further adopted and analyzed by the methods previously 
described by Danes et al (167).  
  
2.2.7 Luciferase reporter assay  
 
The LDHA promoter fragments were amplified from a bacterial artificial 
chromosome (#RP11-107C21) and cloned into a pGL3-basic vector (Promega). The 
promoter constructs were co-transfected with a Renilla luciferase control reporter vector 
into cells using the Amaxa HMEC Nucleofector kit, program T-24 (Lonza). 
Bioluminescence activity was assessed by methods previously described (154). The 
primers for different fragments are listed as following.  
 
Fragment Forward primer sequence  Reverse primer sequence 
-2000 to +272 5’GTTCTGCCTAAGAAGCCTG
AAGCTGTG 
5’GTCAGCATAGCTGTTCCACT
TAA 
-2000 to -1 5’GTTCTGCCTAAGAAGCCTG
AAGCTGTG 
5’ TGCTCCACGTGCGCTGGG 
-500 to -1 5’GCAGAATAAAATGTACATTT
GAACTGAGTCACC 
5’ TGCTCCACGTGCGCTGGG 
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+1 to +272 5’AGCAGCGTCGAGTTTTGGA
GGTCA 
5’GTCAGCATAGCTGTTCCACT
TAA 
+1 to +85 5’AGCAGCGTCGAGTTTTGGA
GGTCA 
5’GTGGGTTCCCGCACGTCCG 
+1 to +33 5’AGCAGCGTCGAGTTTTGGA
GGTCA 
5’CCCGGGCCTCTCCAGTGC 
+85 to +150 5’TCACACGTGGGTTCCCGC 5’ TTAAGTGGAACAGCTATG 
 
2.2.8 Chromatin Immunoprecipitation (ChIP) Assay 
 
ChIP assays were performed following previously described methods (198). 
Immunoprecipitation antibodies: phospho-CREB and IgG antibodies (#9198 and #2729, 
Cell Signaling). Primers for qPCR: Fwd 5’-TGGCTCGGCATCCAC-3’ and Rev 5’- 
CTGCAGCACTCTGAGCTG-3’. 
 
2.2.9 siRNAs and chemical inhibitors  
 
siRNA negative control #1 and siRNAs were purchased from Sigma for 
CREB(SAS1-Hs01_00116985), MYC (SAS1-Hs01_00215897), ATF1 (SAS1-
Hs02_00313621), USF1(SAS1-Hs01_00185068), and SP1 (SAS1-Hs01_00070994) 
knockdown in vitro. Cells were transfected with siRNAs using Pepmute siRNA 
Transfection Reagent (SignaGen Laboratories) according to manufacturer’s protocol. The 
final siRNA concentration was 25nM for each transfection. AZD6244 (Selumetinib) was 
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obtained from Selleck Chemicals and AdooQ Bioscience (#A10257). AZD6244 (10μM) 
was used to treat cells in vitro for at least 5 hours prior to lysate collection from cell culture. 
 
2.2.10 Three-dimensional (3D) culture and immunofluorescence staining  
 
Human non-transformed mammary epithelial cells (hMECs), MCF10A and 
MCF12A, were cultured in 100% matrigel (BD Biosciences, USA) for 3D morphogenesis. 
The 3D culture of hMECs on a matrigel results in a polarized, acini-like spheroids that 
recapitulate ductal and glandular structure in vivo. Cells (2x103) were suspended in 2% 
Matrigel medium, placed in an 8-well chamber slide precoated with Matrigel (#356231, 
BD Biosciences, San Jose). The cells were then fixed with 4% paraformaldehyde and 
stained with mouse monoclonal anti–laminin V (Millipore, Bellerica), rabbit polyclonal anti-
Ki67 (Cell Signaling Technology, Danvers), and rabbit polyclonal anti-cleaved caspase-3 
(Cell Signaling Technology) antibodies using methods described previously described 
previously by Debnath et al. (199). Immunofluorescence staining was analyzed using a 
Zeiss 520 confocal microscope (Carl Zeiss AG, Germany). 
 
2.2.11 Tumor xenograft studies 
 
All the mouse experiments were carried out in accordance with protocols approved 
by MD Anderson’s Institutional Animal Care Committee. We established breast cancer 
xenografts by injecting 5x105 MCFDCIS.COM.Vec or MCFDCIS.COM.ζ cells 
orthotopically into the mammary fat pads of 6-week-old female SWISSnu/nu mice obtained 
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from MD Anderson’s Department of Experimental Radiation Oncology. We then divided 
the mice randomly into two groups, AZD6244 treatment or vehicle control group. Each 
group contained 5 mice. AZD6244 was suspended in sterile HPMC solution and given to 
mice through oral gavage daily at a dose of 16 mg/kg body weight or with vehicle control. 
Tumor volume was calculated using the formula volume = length x (width)2/2 previously 
described by Tomayko and Reynolds (200). Mice were sacrificed 20 days after treatment 
started and tumors were collected and embedded in paraffin following a routine 
pathological procedure. 
 
2.2.12 Immunohistochemistry (IHC) analyses and tissue microarray (TMA) 
 
For general immunohistochemistry (IHC), mouse tumor tissues were embedded in 
paraffin and cut into slides. We used the following antibodies: anti-14-3-3ζ (clone C-19, 
Santa Cruz Biotechnology, Santa Cruz, CA); anti-β-actin (Sigma, Australia); anti-LDHA, 
anti-cAMP response element-binding protein (CREB), anti-phospho-CREB, anti-ERK, 
anti-phospho-ERK (catalog no. 3582, 9197, 9198, 4695, and 4370, respectively, Cell 
Signaling Technology); anti-Ki67 (catalog no. ab92353, AbCam, England); and anti–
minichromosome maintenance 2 (MCM2) (clone EP40, Epitomics). We also used the In 
Situ Cell Death Detection Kit (Roche, Germany) to detect apoptosis in tissue sections. 
The IHC staining scores for 14-3-3ζ, p-CREB, CREB, p-ERK and ERK were defined as 
0, 1+, 2+, or 3+. 3+ indicates higher expression; 1+ indicates lower expression. The 
staining scores for Ki67 defined as percentages. Antigen retrieval and IHC analyses were 
performed as described previously (162). For TMA, we used a 70-case, 208-core breast 
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cancer tissue microarray (catalog no. BR208, US Biomax Inc.). The antigen retrieval and 
staining process are adopted using general IHC protocol. The optimal antibody dilutions 
for IHC is 1:100 as working solution. 
 
2.2.13 Statistical analyses 
 
Between-group differences were assessed using the Student’s t test or ANOVA. P 
values < 0.05 were considered statistically significant.   
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2.3 Results  
2.3.1 14-3-3ζ overexpression increases glycolysis  
Since metabolic dysregulations has recently been implicated to take place during 
the early-stage of neoplastic transformation (103, 171), and abnormal 14-3-3ζ 
overexpression was also observed in pre-cancerous breast lesions (167), I hypothesized 
that 14-3-3ζ overexpression contributes to metabolic dysregulations in early-stage breast 
cancer. To gain insights on this conjecture, I first examined the relationship between 14-
3-3ζ expression and genes involved in metabolic functions, using a microarray dataset 
(GSE16873) generated from histologically normal epithelia, simple ductal hyperplasia 
(SDH), atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) (201). 
Remarkably, the 14-3-3ζ expression level was most strongly correlated with the 
expressions of genes involved in glycolysis (Gene Ontology, GO: 0006096) in these pre-
cancerous and early-stage breast lesions (Figure 13). In addition, this strong correlation 
between 14-3-3ζ expression level and glycolytic genes persisted in breast cancer patients 
(GSE2109 and TCGA datasets) (Figure 14 and 15) (194).  
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Figure 13. The correlation between 14-3-3ζ expression levels and glycolytic genes. Heat 
map of pairwise correlation on 14-3-3ζ (YWHAZ) and glycolytic gene (Gene Ontology, 
GO:0006096) expression levels in the early-stage breast lesions (GSE16873). Triangles 
indicate the high correlation between 14-3-3ζ and LDHA. The correlative relationship 
between the expression levels of 14-3-3ζ (YWHAZ) and LDHA reaches R2>0.8. The data 
are in collaboration with Dr. Chenyu Zhang. 
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Figure 14. Heat map of pairwise correlation on 14-3-3ζ and glycolytic gene 
expression. Heat map of pairwise correlation in breast cancer patients profiled with 
cDNA microarray (expO, GSE2109). The datasets contain data from 353 breast cancer 
patients. Five 14-3-3ζ (YWHAZ) probe sets were analyzed together with glycolysis-
related genes (GO: 0006096). Probe sets were ordered according to clustering analysis. 
Arrow indicates the strong correlation between 14-3-3ζ and LDHA. The correlative 
relationship between the expression levels of 14-3-3ζ (YWHAZ) and LDHA reaches 
R2=0.31. The data are in collaboration with Dr. Chenyu Zhang.   
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Figure 15. The correlation between 14-3-3ζ and glycolytic gene expression in TCGA. 
Heat map of pairwise correlation on 14-3-3ζ (YWHAZ) and glycolytic gene expression 
levels in the TCGA breast cancer datasets. Arrow and indicates the high correlation 
between 14-3-3ζ and LDHA. The correlative relationship between the expression levels 
of 14-3-3ζ (YWHAZ) and LDHA reaches R2=0.32. The data are in collaboration with Dr. 
Chenyu Zhang.  
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To test whether 14-3-3ζ functionally modulates cellular glycolytic activity in pre-
cancerous mammary epithelial cells, I measured glycolytic activities in widely used and 
validated models of pre-cancerous mammary epithelial cells, i.e., MCF10A and MCF12A 
hMECs. I compared three glycolytic indices (i.e., glucose uptake, lactate production, and 
oxygen consumption) in MCF10A and MCF12A hMECs that had either exogenous 14-3-
3ζ overexpression (10A.ζ and 12A.ζ cells) or endogenous 14-3-3ζ knockdown (10A.shζ, 
and 12A.shζ cells) (Fig. 16A) (154). Indeed, glucose uptake and lactate production 
significantly increased in both 10A.ζ and 12A.ζ cells compared to this control cells, but 
significantly reduced in both 10A.shζ, and 12A.shζ cells compared to their control cells 
(Figure 16B and 16C). Cells with higher glycolysis activity tend to reduce the rates of 
oxidative phosphorylation and oxygen consumption and shift the metabolic flux from the 
ATP-generating Krebs cycle to the biomass-producing glycolysis. Consistently, the 
oxygen consumption rates of the 14-3-3ζ-overexpressing 10A.ζ and 12A.ζ cells were 
significantly reduced than that of the control cells (Figure 16D). However, no significant 
difference in oxygen consumption was detected between the 10A.shζ and 12A.shζ cells 
and their control cells (Figure 16D), suggesting that 14-3-3ζ does not modulate basal 
oxygen consumption in the 14-3-3ζ low-expressing MCF10A and MCF12A cells. Next, I 
evaluated the overall impact of 14-3-3ζ on cellular glycolytic activity by calculating the 
glycolytic index, G x L / O, where G is for glucose uptake rate, L is for lactate generation 
production, and O is for oxygen consumption rate (197). 14-3-3ζ-overexpressing 10A.ζ 
and 12A.ζ cells had 4 to 5 fold increases, whereas 14-3-3ζ knockdown 10A.shζ and 
12A.shζ cells had approximately 70% decreases, in their glycolytic index compared to 
their respective control cells (Table 2A and 1B). Collectively, these data demonstrate that 
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14-3-3ζ positively modulates glycolytic activity in nontransformed MCF10A and MCF12A 
cells.  
 
Figure 16. Overexpression of 14-3-3ζ increases glycolysis in hMECs. A, western 
blotting for 14-3-3ζ protein expression in hMEC sublines. B-D, MCF10A and MCF12A 
cells with 14-3-3ζ-overexpression (10A.ζ and 12A.ζ) and 14-3-3ζ-knockdown (10A.shζ 
and 12A.shζ) were assessed for glucose uptake (B), lactate production (C), and oxygen 
consumption (D). The relative levels of glucose uptake, lactate production, and oxygen 
consumption of the 10A.ζ cells and 12A.ζ cells were normalized to those of the control 
10A.Vec and 12A.Vec cells, respectively; and the relative levels of glucose uptake, lactate 
production, and oxygen consumption of the 10A.shζ cells and 12A.shζ cells were 
normalized to those of the control 10A.shCtrl and 12A.shCtrl cells, respectively. Absolute 
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measurements were normalized to the corresponding controls. Bars indicate standard 
deviations. ***, P<0.001; n.s., not significant by the Student t-test.  
 
 
 
 
Table 2. Cellular glycolytic index of 14-3-3ζ-overexpressing and 14-3-3ζ-knockdown 
hMECs. A. The glycolytic activity of 14-3-3ζ overexpressing 10A.ζ and 12A.ζ cells was 
significantly increased than that of control 10A.Vec and 12A.Vec cells. B. the glycolytic 
activity of 14-3-3ζ-knockdown 10A.shζ and 12A.shζ cells was significantly reduced than 
that of control shRNA-transfected 10A.shCtrl and 12A.shCtrl cells.  
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2.3.2 14-3-3ζ-mediate LDHA upregulation increases aerobic glycolysis  
To investigate the molecular mechanisms of the 14-3-3ζ-mediated increase of 
glycolysis, we focused on LDHA because its expression, compared with that of other 
glycolytic genes in human pre-cancerous lesions, is more strongly associated with 14-3-
3ζ expression level. Furthermore, 14-3-3ζ-overexpressing 10A.ζ and 12A.ζ cells had 
significantly increased levels of LDHA mRNA and protein expression compared to their 
vector control cells; whereas knockdown of 14-3-3ζ in 10A.shζ and 12A.shζ cells led to 
significantly decreased LDHA mRNA and protein levels compared to the control shCtrl 
cells (Figure 17A and 17B). 
These findings led us to investigate whether 14-3-3ζ-mediated LDHA upregulation 
directly contributes to the increase of glycolytic activity. We knocked down the LDHA gene 
expression in the 14-3-3ζ overexpressing 10A.ζ and 12A.ζ cells by shRNA 
(10A.ζ.shLDHA and 12A.ζ.shLDHA cells) and measured the three glycolytic indices. The 
10A.ζ.shLDHA and 12A.ζ.shLDHA cells had significantly less glucose uptake and lactate 
production than the control cells (Figure 17C and 17D); whereas oxygen consumption in 
10A.ζ.shLDHA and 12A.ζ.shLDHA cells was not significantly different from that in the 
control cells (data not shown). Overall, the glycolytic indices were reduced with LDHA 
knockdown by approximately 70% (10A.ζ.shLDHA versus 10A.ζ.shCtrl cells) and 60% 
(12A.ζ.shLDHA versus 12A.ζ.shCtrl cells) (Table 3). Together, these data indicate that 
14-3-3ζ-mediated LDHA upregulation is a key promoting factor of glycolysis in 14-3-3ζ 
overexpressing hMECs. 
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Figure 17. 14-3-3ζ overexpression increases glycolysis by upregulating LDHA in 
hMECs. A-B, qRT-PCR analysis of relative LDHA mRNA expression (A), western blotting 
for LDHA protein expression (B) in 14-3-3ζ overexpressing (10A.ζ and 12A.ζ) and 14-3-
3ζ-knockdown (10A.shζ and 12A.shζ) MCF10A and MCF12A cells, compared to control 
cells. C-D, 14-3-3ζ overexpressing cell lines with LDHA knockdown (10A.ζ.shLDHA and 
12A.ζ.shLDHA) were assessed for glucose uptake (C) and lactate production (D). The 
relative levels of glucose uptake and lactate production were normalized to those of the 
shCtrl cells, respectively. Bars indicate standard deviations. *, P<0.05; **, P<0.01; ***, 
P<0.001 using the Student t-test.  
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Table 3. Glycolytic activity of 14-3-3ζ-overexpressing hMECs with LDHA 
knockdown. 10A.ζ and 12A.ζ cells transfected with LDHA shRNA (10A.ζ.shLDHA and 
12A.ζ.shLDHA); or with control shRNA (10A.ζ.shCtrl and 12A.ζ.shCtrl). The glycolytic 
activity of hMECs cells was calculated by glycolytic index.  
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2.3.3 14-3-3ζ-mediated LDHA upregulation contributes to early-stage 
transformation of hMECs  
As increased glycolysis has been implicated in early-stage neoplastic 
transformation (62), we examined whether 14-3-3ζ-mediated LDHA upregulation is a 
critical determinant of hMEC transformation. We previously reported that 14-3-3ζ 
overexpression in MCF10A cells (10A.ζ) led to increased colony formation in soft agar 
and dysregulated acini (158, 167). The 3D culture of normal hMECs on a matrigel results 
in a polarized and acini-like spheroids that recapitulate normal ductal architecture in vivo. 
When oncogene induces cell transformation, which results in a dysregulated acini 
structure that mimics several aspects of early transformation of mammary gland in vivo. 
Consistent with our previous findings in MCF10A cells, the colony numbers of 14-3-3ζ-
overexpressing MCF12A cells (12A.ζ) were also significantly increased compared to 
vector control (12A.Vec) cells (Figure 18A). Remarkably, LDHA knockdown in 14-3-3ζ-
overexpressing MCF10A (10A.ζ.shLDHA) and MCF12A (12A.ζ.shLDHA) cells reversed 
the transforming effects of 14-3-3ζ overexpression, yielding significantly fewer colonies 
compared to their control cells (Figure 18A and Figure 19A).  
Furthermore, in the 3D culture system, 14-3-3ζ-overexpressing 12A.ζ cells also 
developed dysregulated acini with filled lumen resulting from reduced apoptosis (Figure 
18B) and increased proliferation (202) (Figure 18C) compared to control 12A.Vec cells. 
Notably, LDHA knockdown in 14-3-3ζ high expressing 10A.ζ and 12A.ζ (10A.ζ.shLDHA 
and 12A.ζ.shLDHA) partially reversed the dysregulated acini phenotype with increased 
cleaved-caspase 3 (Figure 18B, and Figure 19B), suggesting that LDHA has an anti-
apoptosis effect in hMECs. In addition, 12A.ζ.shLDHA cells had reduced proliferation 
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(reduced both Ki67 and MCM2 levels) but 10A.ζ.shLDHA showed a mild reduction in 
proliferation (Figure 18C and Figure 19C). Further analysis revealed that the 
10A.ζ.shLDHA and 12A.ζ.shLDHA cells had fewer disruptive acini structures and more 
rounding acini than their control cells (Figure 18D and Figure 19D), demonstrating a 
partial restoration of normal epithelial morphology. Collectively, these data demonstrate 
that 14-3-3ζ overexpression-mediated LDHA upregulation contributes, at least partially, 
to hMEC transformation and aberrant acinar formation through, increased glycolysis, 
increased proliferation, and decreased apoptosis that can be reversed by LDHA 
downregulation.  
  
- 62 - 
 
 
Figure 18. The contributions of 14-3-3ζ-mediated LDHA upregulation in hMECs. A, 
Quantified soft colony formation assay of the MCF12A sublines. Cells were cultured in 
0.5% soft agar for 21 days. B, Detection of apoptosis (cleaved caspase 3, green), polarity 
markers (Laminin V, red) and DAPI (blue) in MCF12A sublines cultured in Matrigel for 8 
days. Left: Right: Western blotting of cleaved caspase-3 and 14-3-3ζ in acini lysate 
collected from 3D culture. C, Detection of proliferation marker (Ki-67, green), polarity 
marker (Laminin V, red) and DAPI (blue) in MCF12A sublines cultured in 3D culture for 
15 days. Scale bars, 50 μm. Right: Western blotting of MCM2, and 14-3-3ζ in acini lysate 
collected from 3D culture. D, MCF12A sublines in 3D culture for 20 days, rounded or 
disrupted acinar morphology were counted.   
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Figure 19. LDHA upregulation contributes to early-stage transformation of MCF10A 
cells. A, Quantified soft colony formation assay of the MCF10A sublines which were 
cultured in 0.5% soft agar for 45 days, and the cell colonies were counted. B, Detection 
of apoptosis (cleaved caspase-3, green) and polarity marker (laminin V, red) and DAPI 
(blue) in MCF10A sublines cultured in Matrigel. Representative images of 
immunofluorescence staining. Scale bars, 50 μm. C, Detection of proliferation markers 
(Ki-67, green), polarity marker (laminin V, red), and DAPI (blue) in MCF10A sublines 
cultured in Matrigel. Representative images of MCF10A sublines subjected to 
immunofluorescence staining. D, MCF10A sublines cultured for 30 days were assessed 
for rounded or disrupted acinar morphology.  
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2.3.4 14-3-3ζ overexpression leads to up-regulation of LDHA  
Since LDHA upregulation contributes to 14-3-3ζ-mediated hMEC transformation, 
it is important to identify the underlying molecular mechanisms of 14-3-3ζ-induced LDHA 
upregulation. Because 14-3-3ζ overexpression increases LDHA expression at both 
mRNA and protein levels in hMECs (Figure 17A and 17B) and is known to regulate protein 
stability (157, 203), I initially compared the LDHA protein stability of the 10A.ζ cells with 
that of the control 10A.Vec cells, but found no significant difference between them (Figure 
20A and 20B). This led us to focus on studying mechanisms of LDHA mRNA upregulation 
by 14-3-3ζ. I examined LDHA mRNA stability by treating 10A.ζ and 10A.Vec cells with 
actinomycin D, and measured LDHA mRNA degradation rate. No significant difference in 
LDHA mRNA stability was found between the 10A.ζ and 10A.Vec cells (Figure 20C), 
suggesting that 14-3-3ζ might modulate LDHA mRNA expression through transcriptional 
regulation.      
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Figure 20. Comparison between protein and mRNA stability in hMECs. A-B, MCF10A and 
MCF12A sublines were treated with 100 µg/mL cycloheximide (CHX) from 0 to 24 hours 
and compared the LDHA degradation rate over the time. Myc served as a positive control 
to show that CHX worked effectively during treatment. The LDHA expression levels were 
normalized to β-actin and also to their time zero of treatment. C, MCF10A sublines were 
treated with actinomycin D from 0 to 2 hours and compared the mRNA level of LDHA over 
the time. The LDHA mRNA expression levels were normalized to 18s and also to their 
time zero of treatment. 
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To determine whether 14-3-3ζ transcriptionally upregulates LDHA, I cloned the 
LDHA promoter from 2000 base pairs (bp) upstream of the transcription start site plus the 
entire 272bp 5’-untranslated region (5’-UTR) into the pGL3-Basic vector to drive 
luciferase reporter gene expression (-2000 to +272-Luc), and transfected this reporter 
vector into the 10A.ζ versus 10A.Vec cells and the 10A.shζ versus 10A.shCtrl cells (Fig. 
4A). I detected an increase of luciferase activity in 10A.ζ compared to 10A.Vec cells, but 
a decreased luciferase activity in 10A.shζ compared to 10A.shCtrl cells, indicating that 
14-3-3ζ transcriptionally upregulates LDHA mRNA expression (Figure 21A).   
To identify the cis-regulatory element in the -2000bp LDHA promoter and 5’-UTR 
region that is responsible for 14-3-3ζ-induced transcriptional upregulation, I made a series 
of deletion constructs in the -2000 to +272 region, subcloned them into the pGL3-Basic 
vector, and transfected them into the 10A.ζ, 10A.Vec, 10A.shζ, and 10A.shCtrl cells (Fig. 
21A, left). Remarkably, a specific 65bp region (+85 to +150) in the 5’-UTR of LDHA gene 
was necessary and sufficient to induce the luciferase gene expression (Figure 21A). 
Transfection of this 65bp 5’-UTR region resulted in higher luciferase activity in 10A.ζ than 
in vector control cells (Figure 21A, middle). In contrast, the luciferase activity driven by 
the 65bp 5’-UTR was lower in the 10A.shζ cells compared to the 10A.shCtrl cells (Figure 
21A, right). Next, to identify the transcription factors that bind to the 65bp 5’-UTR region 
of LDHA and are responsible for transcriptional upregulation by 14-3-3ζ, I analyzed this 
DNA sequence for putative transcription factor binding sites using the Transcription 
Element Search System (TESS) and University of California-Santa Cruz (UCSC) genome 
browser online analysis tools  (204, 205). I identified potential binding sites for five 
transcription factors USF1, CREB, MYC, SP1, and ATF-1 (Figure 21B), knocked them 
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down individually in the 10A.ζ cells and compared their luciferase activities. Knocking 
down each of the five genes reduced the LDHA 65bp 5’-UTR driven luciferase activity in 
10A.ζ cells to various degrees, and knocking down CREB led to the most significant 
reduction (Figure. 21C). 
Furthermore, I examined LDHA mRNA and protein levels in the 10A.Vec and 10A.ζ 
cells that had the five transcription factors knocked down individually. Among these five 
transcription factors, CREB and MYC knock down in the 10A.ζ cells (Figure 21D and 21E), 
significantly reduced LDHA protein and mRNA compared to shCtrl cells (Figure 21F and 
21G). However, CREB knockdown had less effect on the LDHA protein level in the control 
10A.Vec cells compared to MYC knockdown cells (Figure 21F), suggesting that CREB 
has a more specific role in regulating LDHA expression in 14-3-3ζ overexpressing cells. 
Therefore, I focused on the question how 14-3-3ζ overexpression leads to CREB 
transactivation of LDHA that contributes to early transformation in 14-3-3ζ overexpressing 
hMECs. 
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(Legends of Figure 21 were listed in the next page) 
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Figure 21. Identification of transcription factors involved in LDHA upregulation. A, 
Schematic design of the LDHA regulatory region deletion assay. Series of deletion 
constructs were transfected into 10A.ζ, 10A.Vec, 10A.shζ and 10A.shCtrl cells. B, 
Schematic overview of the transcription factor binding sites from +1 to +272 bp of LDHA’s 
5'-UTR annotated using the TESS. C, Cells with individual knockdown of five indicated 
transcription factors were subject to luciferase activity assays after transfection with the 
construct with the 65bp 5’UTR region driving the luciferase reporter gene. The relative 
luciferase activity of the cells was normalized to that of 10A.ζ cells with control siRNA. D, 
qRT-PCR analysis of relative CREB mRNA and E) MYC mRNA expression in the 
indicated cells was normalized by 18s mRNA expression. F, Western blotting of c-Myc, 
CREB, LDHA, and 14-3-3ζ in MCF10A sublines. G, qRT-PCR analysis of relative LDHA 
mRNA expression in cells with five transcription factors individually knocked down and 
control cells 
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14-3-3ζ has been shown to directly bind to Raf and activate MEK/ERK (206-208), 
which directly phosphorylate p90 ribosomal S6 kinase, that in turn activates and 
phosphorylates of CREB at Ser-133 (209, 210). Thus, I tested whether CREB-mediated 
transcriptional upregulation of LDHA could be modulated through the 14-3-3ζ-ERK-RSK 
signaling axis. Indeed, I detected a dramatically higher activation of the ERK pathway and 
increased phosphorylation of CREB at Ser-133 in both 10A.ζ and 12A.ζ cells compared 
to control 10A.Vec and 12A.Vec hMECs (Figure 22A). Furthermore, treating the 14-3-3ζ-
overexpressing 10A.ζ and 12A.ζ cells with a potent MEK/ERK inhibitor, AZD6244, 
dramatically inhibited the ERK pathway, reduced CREB phosphorylation and decreased 
the LDHA mRNA and protein expressions to similar levels as in the 10A.Vec and 12A.Vec 
hMECs (Figure 22B and 22C), suggesting that LDHA upregulation in the 14-3-3ζ 
overexpressing 10A.ζ and 12A.ζ cells is primarily dependent on the ERK/CREB pathway. 
To determine whether the transcription factor CREB directly binds to the LDHA promoter, 
I performed chromatin immunoprecipitation assay using anti-p-Ser-133-CREB followed 
by LDHA promoter-specific PCR (ChIP-PCR). I found significantly more LDHA promoter-
bound pCREB proteins (~1.8 to 2 fold) in the 14-3-3ζ-overexpressing 10A.ζ and 12A.ζ 
cells than in the control cells (Figure 22D). In contrast, knockdown of 14-3-3ζ in MCF10A 
hMECs significantly reduced pCREB protein binding to the LDHA promoter compared to 
the 10A.shCtrl cells (Figure 22D). Together, these data indicate that 14-3-3ζ 
overexpression activates the MEK/ERK pathway and consequently increases the binding 
of pCREB to the LDHA promoter, leading to LDHA transcriptional upregulation. 
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Figure 22. 14-3-3ζ overexpression transcriptionally upregulates LDHA. A, Western 
blotting of c-Myc, CREB, LDHA, and 14-3-3ζ in MCF10A sublines. B, Western blotting 
detecting the phospho-ERK, phospho-CREB, total ERK, CREB, LDHA, and 14-3-3ζ 
in10A.Vec, 10A.ζ, 12A.Vec and 12A.ζ cells treated with AZD6244 or DMSO. C, qRT-PCR 
analysis of LDHA mRNA expression in the hMEC sublines following by treatment with 
AZD6244 or DMSO. D, Chromatin immunoprecipitation assay using anti-phospho-CREB 
(Ser-133) followed by PCR (ChIP-PCR) of the LDHA promoter region.   
A 
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2.3.5 Targeting the MEK/ERK/CREB pathway inhibits tumor outgrowth 
Because the MEK/ERK/CREB pathway is critical for 14-3-3ζ-induced LDHA 
upregulation which contributes to hMEC early transformation. I proposed that targeting 
this pathway to inhibit metabolic adaptation of early-stage breast cancer cells towards 
glycolysis may be an effective strategy to intervene cancer progression. Therefore, I next 
investigated whether targeting the 14-3-3ζ downstream from the MEK/ERK pathway may 
effectively prevent or intervene the early-stage breast cancer further progression in vivo. 
To this end, I exogenously overexpressed 14-3-3ζ in early-stage DCIS model of 
MCF10DCIS.COM cells. The MCF10DCIS.COM line is a MCF10A cells-derived model 
that forms DCIS-like mammary lesions and ultimately progresses to invasive mammary 
tumors in nude mice (195). Recent studies revealed almost identical genomic profiles 
between the MCF10A and MCF10DCIS.COM cells, supporting our efforts to extend the 
above studies of MCF10A to in vivo investigations using the MCF10DCIS.COM line (211). 
Consistent with the MCF10A and MCF12A cells, exogenous overexpression of 14-3-3ζ 
in the MCF10DCIS.COM cells (DCIS.COM.ζ) led to activation of the ERK/CREB pathway 
and LDHA upregulation; whereas 14-3-3ζ knockdown in MCF10DCIS.COM led to 
decreased ERK/CREB activity and LDHA downregulation (Figure 23 and Figure 24). 
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Figure 23. DCIS.COM breast cancer cells. Western blotting of proteins in DCIS.COM 
sublines. 
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Figure 24. Figure 24. Representative IHC staining of DCIS.COM.Vec and DCIS.COM 
tumors. 14-3-3ζ, phospho-ERK, ERK, phospho-CREB, CREB, and LDHA in 
DCIS.COM.Vec and DCIS.COM.ζ tumors with indicated treatments. Scale bars, 50 μm. 
The data are in collaboration with Dr. Qingling Zhang.   
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Next, I implanted DCIS.COM.ζ and control DCIS.COM.Vec cells into the mammary 
fat pads (m.f.ps) of nude mice (day 0) to produce tumor xenografts and started treating 
these mice with vehicle or MEK/ERK inhibitor AZD6244 on day 10 (Figure 25A). 
Treatment continued until day 30, when the mice were sacrificed and their mammary 
tumors were collected. Vehicle-treated 14-3-3ζ overexpressing DCIS.COM.ζ 
(DCIS.COM.ζ.Vehicle) tumors had significantly higher tumor growth rate compared to 
vehicle-treated DCIS.COM.Vec (DCIS.COM.Vec.Vehicle) tumors (Figure 25B), 
suggesting that overexpression of 14-3-3ζ can promote tumor outgrowth. Interestingly, 
AZD6244 inhibited >75% DCIS.COM.ζ tumor growth but <50% DCIS.COM.Vec tumor 
growth, suggesting that the 14-3-3ζ overexpressing DCIS.COM.ζ tumors were more 
dependent on the MEK/ERK pathway and its downstream targets. These data indicate 
that 14-3-3ζ overexpression-mediated tumor progression in this DCIS model can be 
effectively targeted by MEK/ERK inhibitor.  
To determine the impact of MEK/ERK inhibitor treatment on 14-3-3ζ/ERK/CREB/ 
LDHA, as well as on tumor cell proliferation and apoptosis, I collected tumors from control 
and treatment groups. IHC showed that 14-3-3ζ overexpressing DCIS.COM.ζ tumors had 
increased phospho-ERK and phospho-CREB levels that correlated with higher LDHA 
expression compared with DCIS.COM.Vec tumors (Figure 25C) but had no significant 
effect on total ERK, CREB or 14-3-3ζ expression levels (Figure 24). AZD6244 treatment 
significantly reduced phospho-ERK, phospho-CREB and LDHA levels in DCIS.COM.ζ 
and DCIS.COM.Vec tumors compared to vehicle treatment (Figure 25C and Table 4). 
Compared to the DCIS.COM.Vec.Vehicle tumors, the DCIS.COM.ζ.Vehicle tumors 
showed no significant difference in apoptosis, but a singnificantly increased Ki67 positive 
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proliferating cells (Figure 25C and 25D), which were inhibited by AZD6244 (Figure 25C 
and 25D). These data indicate that AZD6244 effectively inhibit the 
MEK/ERK/CREB/LDHA axis and proliferation of 14-3-3ζ overexpressiong tumor cells, 
thereby suppressing DCIS-like tumor outgrowth. 
 
 
 
Figure 25. AZD6244 treatment inhibits DCIS.COM.ζ tumor growth. A. Experimental 
design of treating the DCIS.COM.Vec and DCIS.COM.ζ m.f.p. tumors in nude mice. After 
DCIS.COM.Vec and DCIS.COM.ζ xenograft tumors were established by day 10, mice 
were treated with vehicle or AZD6244 daily. B, The relative tumor volume of 
DCIS.COM.Vec.Vehicle and DCIS.COM.ζ.Vehicle were compared with their AZD6244 
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treatment groups, respectively. Bars indicate standard deviations. C, Representative 
images of IHC staining of phospho-ERK, phospho-CREB (Ser-133), LDHA and Ki-67 in 
DCIS.COM.Vec and DCIS.COM.ζ xenograft tumors from mice treated with vehicle and 
AZD6244. Scale bars, 50 μm. D, Quantitative analysis of Ki-67-positive cells in 
DCIS.COM.Vec and DCIS.COM.ζ xenograft tumors. *, P<0.05; ***, P<0.001 by the 
Student t-test. The data are in collaboration with Dr. Qingling Zhang. 
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Xenografts 
 
Marker 
DCIS.COM.Vec DCIS.COM.ζ 
Vehicle Vehicle AZD6244 P Value 
14-3-3ζ 1.6±0.245 2.6±0.245 2.2±0.200 P=0.2415 
pERK 1.6±0.400 2.8±0.200 1.6±0.245 P=0.0053** 
pCREB 2.4±0.245 3.0±0.000 2.2±0.200 P=0.0039** 
LDHA 1.6±0.245 2.6±0.245 1.6±0.245 P=0.0203* 
Ki-67 23%±4.359 37%±5.831 10%±2.739 P=0.0006*** 
TUNEL 4±1.673 3.2±0.583 4.4±1.631 P=0.508 
Table 4. Quantitative analyses of IHC staining of the ERK/CREB signaling pathways. 
The IHC staining scores for 14-3-3ζ, p-CREB, LDHA were defined as 0, 1+, 2+, 3+, which 
indicate different level of expression. The Ki-67 index was defined as the percentage of 
Ki-67 positive cells on slides and the TUNEL index was counted the TUNEL positive cells 
on slides. P value was calculated between vehicle and AZD6244 treated DCIS.COM.ζ 
tumors. * indicates P<0.05, ** indicates P<0.01 and *** indicates P<0.001 by the Student 
t-test.  
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2.3.6 14-3-3ζ-LDHA axis as potential biomarkers  
Having established that the 14-3-3ζ-mediated MEK/ERK/LDHA axis is potently 
active in nontransformed hMECs and highly correlated in early neoplastic breast lesions 
(R2>0.8) (Figure 13). Next, I extended our examination by bioinformatics analysis of 
datasets generated from breast cancers. I found that the correlative relationship between 
the expression levels of 14-3-3ζ (YWHAZ) and LDHA reached R2 of 0.31 and 0.32 (Figure 
14 and Figure 15) in microarray-derived dataset GSE2109, and RNAseq-derived TCGA 
dataset (193, 194), respectively. The strength of such positive correlation is much weaker 
than that in early-stage diseases (Figure 26A), suggesting that with cancer progression 
into advanced stages, neoplastic cells may have metabolitically adapted to a complex 
tumor environment. Furthermore, when I examined LDHA levels in 14-3-3ζ 
overexpressing established breast cancer cell lines such as, HCC1954 HER2+ and MDA-
MB-231 TNBC, I did not detect a significant up-regulation of LDHA or increase of 
glycolysis. These data suggest that the 14-3-3ζ/CREB/LDHA pathway may be more 
critical in the early-stage breast cancer initiation.  
As the above bioinformatics analyses were performed on RNA data, I further 
evaluated the clinical relevance of 14-3-3ζ/CREB/LDHA axis at protein level using tissue 
microarray (TMA) of mixed stages of breast cancers. Indeed, IHC staining revealed that 
the 14-3-3ζ protein levels were significantly correlated with the LDHA protein levels in 
these breast cancer specimens (Figure 26B and Table 5). Importantly, the 14-3-3ζ 
expression levels were also significantly correlated with CREB phosphorylation in the 
consecutive TMA slides from the same group of patients (Figure 26B and Table 5).  
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Next, to evaluate whether 14-3-3ζ and LDHA levels hold prognostic values for 
breast cancer. As there is no early-lesion dataset with follow-up on clinical outcome, I 
instead used a breast cancer gene expression dataset (GSE3494) with disease-specific 
overall survival data. I found that concomitant high expression of 14-3-3ζ and LDHA 
predicts worse survival of breast cancer patients compared to high expression of either 
gene alone (P=0.00257 vs. P=0.0127 and P=0.0322) (Figure 26C). Furthermore, the 5-
year survival rate for patients with concurrent high expression of both 14-3-3ζ and LDHA 
genes dropped almost 10% compared to high expression of either gene alone (Figure 
26C). Continued, these data suggest that the expression levels of 14-3-3ζ and LDHA 
have a more power in predicting the clinical outcome of breast cancer patients. It is 
possible that 14-3-3ζ and LDHA expression levels together may have an even stronger 
power in predicting the clinical outcome of early-stage disease progression in patients, 
which should be investigated in future studies.  
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Figure 26. 14-3-3ζ-LDHA signaling axis holds prognostic value in predicting clinical 
outcome.  A, Linear regression of the LDHA and 14-3-3ζ (YWHAZ) expression values in 
the TCGA breast cancer dataset. The square of Pearson coefficient R2 is 0.324 and 
P<0.0001. B, Representative images of IHC staining of 14-3-3ζ, phospho-CREB (Ser-
133) and LDHA, in a 208-core human breast cancer tissue microarray (TMA). A total of 
187 (89%) cores were eligible for scoring and examined for the association of 14-3-3ζ 
and phosphor-CREB; a total of 183 (88%) cores were examined the association of 14-3-
3ζ and LDHA. The IHC staining scores for 14-3-3ζ, p-CREB, LDHA were defined as 0, 
1+, 2+, or 3+, where 3+ indicates higher positive expression; and 1+ indicates lower 
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positive expression. Scale bars, 50 μm. C, Kaplan-Meier survival curve of breast cancer 
patients (GSE3494). Concomitant high expression of 14-3-3ζ and LDHA (logrank P<0.01) 
predicts worse outcome than high 14-3-3ζ (YWHAZ) expression level (logrank P<0.05) 
or high LDHA expression level (logrank P<0.05). The data are in collaboration with Dr. 
Qingling Zhang and Dr. Hai Wang. 
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 14-3-3ζ expression    
Marker 0 1+ 2+ 3+ P value R2 N 
LDHA expression        
0 4.2% 4.2% 5.3% 0.0% 
    0.047*  0.242 187 
1+ 5.3% 12.9% 10.6% 2.6% 
2+ 6.4% 16.5% 9.6% 5.8% 
3+ 1.6% 5.8% 3.7% 4.2% 
pCREB expression        
0 9.6% 5.5% 9.3% 0.5% 
0.0006*** 0.245 183 
1+ 0.0% 9.8% 9.3% 4.4% 
2+ 0.0% 6.6% 9.8% 6.0% 
3+ 3.8% 8.2% 12.0% 5.5% 
 
Table 5. Analyses of 14-3-3ζ association with LDHA and pCREB (Ser-133) in 
consecutive tissue microarray (TMA) slides. A total of 187 (89%) specimens were 
examined the association between 14-3-3ζ and LDHA; and a total of 183 (88%) 
specimens were examined the association between 14-3-3ζ and phospho-CREB (Ser-
133). The square of Pearson coefficient R2 is 0.242 between 14-3-3ζ and LDHA; and R2 
is 0.245 between 14-3-3ζ and phospho-CREB. The IHC staining scores for 14-3-3ζ, p-
CREB, LDHA were defined as 0, 1+, 2+, 3+, which indicate different level of expression. 
The square of Pearson coefficient R2 were calculated and indicated the correlation 
relationship. P value was calculated by Chi-square analysis. * indicates P<0.05 and *** 
indicates P<0.001 by Student t-test. 
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2.4 Conclusions 
Mammary tumor progression manifests ten hallmarks of cancers, of which 
metabolic dysregulation is an important tumor-specific alteration (8, 212). Understanding 
the intrinsic link between cancer progression and metabolic alteration could be further 
developed into a promising "metabolic therapy" approach for cancer prevention or 
treatment (212, 213). The Warburg effect is a general phenomenon in cancer cells that 
fuels a high rate of glycolysis in order to produce biological intermediates for biosynthetic 
pathways, satisfying the cells’ needs for active proliferation. Recent studies indicate that 
metabolic alteration may already occur at the early-stage of neoplasms and contribute to 
early transformation (103, 171). Understanding cancer cell metabolism may improve early 
identification and diagnosis for breast cancer treatment (214). Previously, Dr. Jing Lu’s 
work (previous postdoc in my laboratory) have identified that 14-3-3ζ is a critical mediator 
to cooperate with receptor tyrosine-protein kinase 2 (ErbB2) to increase the transition of 
ductal carcinoma in situ (DCIS) to invasive breast cancer (162). The work in this chapter 
now demonstrates that overexpression of 14-3-3ζ in human breast epithelial cells 
upregulates LDHA, contributing to shift metabolic flux toward aerobic glycolysis, thereby 
facilitating cancer initiation and progression (Figure 27)  
A bioinformatics analysis of datasets generated from premalignant breast lesions 
found that the expression level of 14-3-3ζ (YWHAZ) is highly correlated with LDHA 
(R2>0.8) (Figure 13), however, when the disease progressed into late stages of breast 
cancer, the correlation between the 14-3-3ζ and LDHA become very weak. R2 is 0.32 and 
0.31 in TCGA invasive breast cancer dataset (193) and human breast cancer dataset 
(GSE2109), respectively (Figure 14 and Figure 15) (194). The data indicate that 14-3-3ζ-
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mediated LDHA upregulation may be critical for early transformation features, but may be 
less desired for late stages of breast cancer for adaptation in a more complex tumor 
environment. Nonetheless, concurrent high expression of 14-3-3ζ and LDHA can still hold 
prognostic values for disease-specific overall survival for breast cancer (Figure 26C). A 
similar phenomenon was observed in the in vitro models. My works found that 14-3-3ζ 
overexpression clearly induced upregulation of LDHA and aerobic glycolysis in the hMEC 
and MCF10DCIS.COM cells that mimic the early-stage development of breast cancer. 
Intriguingly, further overexpression of 14-3-3ζ in aggressive human breast cancer cell 
lines HCC1954 (HER2 overexpressing breast cancer) and MB-MDA-231 (triple-negative 
breast cancer) did not lead to significantly higher LDHA levels or glycolytic activity. The 
findings suggest that 14-3-3ζ overexpression-induced metabolic dysregulation may be an 
early event during breast cancer initiation and progression, which may serve as a 
metabolic therapy target for early intervention. 
A genome-wide promoter analysis has reported that LDHA is a CREB’s target 
gene due to the conserved c-AMP response element (CRE), TGACGTCA on LDHA 
promoter, which is evolutionarily preserved either within 1000-bp upstream of the ATG 
start codon or within 250-bp of the 5’-UTR element in mouse and human genome (215). 
Transfecting the 65bp region with CRE binding site in 10A.ζ showed significantly higher 
luciferase activity than those with the 2000-bp promoter region (Figure. 21A), which 
suggests that CRE binding sequence is critical for LDHA transcription in 14-3-3ζ-
overexpressing hMECs. Although CREB activation has been reported to be involved in 
multiple signaling transduction (216), my work is the first to demonstrate that 14-3-3ζ 
overexpression-mediated LDHA upregulation is through activation of MEK/ERK/CREB 
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signaling, which is important for early transformation and cancer initiation phenotype. 
Despite c-Myc has been reported as a master mediator for modulating LDHA expression 
in cancer (95, 217), my data suggest that CREB is a key transcription factor to induce 
expression of LDHA in 14-3-3ζ-overexpressing hMECs. Remarkably, the expression of 
14-3-3ζ is strongly associated with the LDHA protein expression and CREB 
phosphorylation level in tissue microarray (TMA) with various stages of breast cancers, 
which validates and determines the importance of our findings. 
Cancer cell metabolism is a cancer hallmark (218, 219), which provides different 
intermediates for cell survive and growth. Targeting aberrant metabolism becomes a 
potential therapeutic strategy (181, 220). However, unlike other targeted therapy which 
could easily distinguish between normal tissues and cancerous tissues in the body, a 
metabolic therapy may lead to high toxicity in tissues and adverse effects by patients. 
Therefore, the dose-limiting toxicity may be a challenge and need further investigation 
along metabolic drug development (114, 115, 221). After establishing the functional roles 
of the 14-3-3ζ/LDHA axis in 14-3-3ζ-mediated glycolysis, further inhibition of MEK/ERK 
pathway with AZD6244 leads to significantly reduced LDHA expression and tumor 
inhibition. The LDHA inhibitor Gossypol (AT-101) has already yielded encouraging results 
in multiple clinical trials (181-183), which may be worthy to further investigate in the future.  
Many lines of study revealed that 14-3-3ζ is involved in numerous cellular 
pathways including therapy resistance, lipid metabolism, anti-apoptosis function, and 
metastasis (154, 222-224). This work suggest a novel link between 14-3-3ζ and cancer 
cell metabolism. In summary, my work demonstrate that 14-3-3ζ is a critical mediator of 
glycolysis, which may contribute to initiation, early transformation and progression of 
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breast cancer. The data in hMEC-derived DCIS preclinical model suggest that intervening 
14-3-3ζ-mediated activation of MEK/ERK pathway can significantly reduce tumor growth. 
These findings have now provided new insights into the mechanistic understanding of 14-
3-3ζ overexpression-mediated early transformation, which may serve as new biomarkers 
and therapeutic targets for early intervention in the clinic. 
Since that chapter 2 has addressed the role of 14-3-3ζ in breast cancer initiation, 
the next chapter (chapter 3) will further focus on the investigation of the pathological role 
of 14-3-3ζ in breast tumor growth and progression. 
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Figure 27. Proposed model of 14-3-3ζ overexpression facilitates breast cancer 
tumorigenesis. Schema showing that 14-3-3ζ overexpression activates the 
MEK/ERK/CREB pathway and transcriptionally upregulates LDHA which contributes to 
increasing glycolysis and promotes cancer initiation and growth. Dotted arrow points out 
that other transcription factors including Myc can regulate LDHA gene expression (95), 
reprogram cancer metabolism and contribute to cancer pathogenesis as well. 14-3-3ζ-
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mediated LDHA upregulation shows the novel functional role of 14-3-3ζ in mediating 
metabolic dysregulation in cancer.  
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Chapter 3 
THE MIF-CXCR2-IL8 PATHWAY IS REQUIRED FOR 14-3-3ζ–
HIGH TUMOR CELLS TO INDUCE CELL COMPETITION 
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3.1 Introduction 
3.1.1 Clonal selection and tumor heterogeneity 
Cancer is an evolutionary process of cell clone selection and expansion (116, 117); 
over time, a clone population arises with an increase in competitive abilities and fitness 
advantages and out-competes other tumor subclones for the limited space and resources 
within tumors (118). Somatic mutation, epigenetic dysregulation, cellular context and 
microenvironment stress contribute to different levels of positive selection of clones for 
fitness, which results in tumor heterogeneity (118, 119). Tumor heterogeneity explains 
the cellular complexity and dynamics that challenge current therapeutic strategies and 
alter treatment effectiveness (123). Understanding clonal evolution and dynamics of cell 
fitness may improve targeted therapy efficacy and enable efficient intervention in tumor 
progression. 
3.1.2 Overview of cell competition 
Cell competition is a type of cell-cell interaction that was originally described in 
Drosophila melanogaster development and is evolutionarily conserved in mammals (225, 
226). The cell competition is initiated when cell populations (“loser” or “unfit” cells) are 
surrounded by better competing cell populations (“winner” or “fit” cells), thereby triggering 
winner-cell-induced apoptosis (227). Interestingly, loser cells can be viable in a homotypic 
environment, which means that the cell death is caused by the percentage of surrounding 
fit cells (225). The mechanism underlying winner-loser competition is that the winner cells 
contain better proliferative capacity and eliminate loser cell through inducing apoptosis, 
perhaps and most likely, through cell–cell contact-dependent signaling. Cell competition 
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is not limited to the defect in the Minute gene described in Drosophila; certain genes, such 
as dmyc, when their overexpression level is above that of the surrounding cells, can 
transform wild-type cells into super-competitors and eliminate neighboring cells (228-230). 
Cell competition has emerged in both tumor suppressor and oncogene function. Previous 
studies have shown that failure to substitute deficient T cell progenitors with healthy bone 
marrow progenitors results in T-lineage acute lymphoblastic leukemia (T-ALL) (231, 232). 
Those studies reveal that cell competition is a powerful tissue surveillance mechanism 
that prevents tumor formation from unfit cells. In addition to such protective efforts, cell 
competition could be exploited by oncogenes and critical for early-stage cancer initiation 
and development (233-236). Other signaling, such as Warts/Hippo pathway and Myc, 
have been shown to modulate tumor growth in Drosophila (237); Especially Myc, one of 
the well-characterized models in Drosophila, was further implied to drive cell competition 
in human cancers (238). It remains elusive how human cancer cells acquire the cell 
competition mechanism for tumor growth and survival during cancer development. 
3.1.3 14-3-3ζ and cell competition mechanism 
14-3-3ζ belongs to a highly conserved protein family and modulates numerous 
pathways in cancer (157). 14-3-3ζ may be relevant to cell competition because many of 
the 14-3-3ζ-mediated cellular networks have been shown to be involved in regulation of 
cell competition. In neoplasms, 14-3-3ζ overexpression induces aerobic glycolysis 
through upregulation of LDHA (159); leads to Akt phosphorylation by activation of the 
PI3K pathway (161); and destabilizes the p53/Smads complex by binding to YAP-1 (154). 
In cancers, 14-3-3ζ overexpression enhances MAPK/c-Jun signaling (163) and regulates 
tumor immune response by modulation of multiple cytokines’ expression (164, 165).  
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Interestingly, quite a number of 14-3-3ζ-mediated cellular networks have been reported 
as involved in cell competition, such as the Hippo pathway, JNK pathway and PI3K-Akt 
pathway (166). These results suggest that cancer cells with high 14-3-3ζ expression may 
hijack cell competition machinery from the developmental stage to promote cancer 
initiation and progression.  
3.1.4 Hypothesis  
14-3-3ζ overexpression occurs at the early neoplastic stage of breast disease and 
persists throughout breast cancer progression (167). I therefore sought to examine the 
role of 14-3-3ζ in cell competition. I found that 14-3-3ζ expression was greatly 
heterogeneous at the neoplastic stage of breast cancer; as disease progressed, the 
expression expanded to 100% of tumor. 14-3-3ζ preferentially accumulated during breast 
cancer development. I therefore hypothesized that tumor cells selectively preserve high 
14-3-3ζ expression and may take over the tumor population through regulating the cell 
fitness mechanism. I identified that cells expressing different levels of 14-3-3ζ responded 
inversely upon macrophage inhibitory factor (MIF) stimulation. 14-3-3ζ-high-expressing 
cells can efficiently sequester MIF in a ligand-limited tumor environment, and reduction 
of MIF stimulation in 14-3-3ζ-low cells led to cell death and gradual elimination of the cells 
from tumors. Taken together, my findings establish a novel role for how 14-3-3ζ exploits 
the inflammatory pathway to drive cell competition and eradicate loser cells. This proof-
of-concept study shows that cancer is a disease caused by cell competition. Targeting 
mechanisms underlying cell competition may reduce oncogene-mediated cell fitness and 
be a potential therapeutic strategy to further inhibit tumor growth. 
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3.2 Materials and Methods  
 
3.2.1 Cell lines and cell culture 
 
HCC1954, HCC70, Hs 578t and BT549 cells were obtained from American Type 
Culture Collection (ATCC) and were cultured in DMEM/F-12 media (Caisson 
Laboratories, USA) supplemented with 10% fetal bovine serum. Cell lines were 
authenticated and characterized by the Characterized Cell Line Core Facility at MD 
Anderson Cancer Center. 
 
3.2.2 Plasmids and shRNAs 
 
Green and red fluorescent protein were constructed into pLOVE lentivirus-based 
vectors (Addgene). To produce lentiviral virus, all shRNA vectors and pLOVE vectors 
were transfected into 293FT cells together with second-generation lentiviral plasmids, 
pMD2.G and psPAX2 (Addgene), through a LipoD293 DNA in vitro transfection Ver. II kit 
(SignaGen Laboratories, USA) according to the manufacturer’s protocol. Lentiviral 
supernatants were collected 48 hours after transfection. Lentiviral particles were 
precipitated and concentrated by PEG-it virus precipitation solution (SBI System 
Biosciences, USA) and freshly used to transduce cells in the presence of 8 μg/ml 
polybrene. For 14-3-3ζ-knockdown lines, cells were transfected with 14-3-3ζ shRNA 
(clone, NM_003406.2-418s1c1 or NM_003406.2-738s1c1, Sigma) or non-targeting 
scrambled shRNA (pLKO.1-puro #SHC002, Sigma) and selected with 2 μg/ml puromycin. 
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For IL-8-knockdown cell lines, HCC1954.Ctrl cells were transfected with IL-8 shRNA 
(NM_000584.2-727s1c1) or non-targeting shRNA (pLKO.1-puro) and selected with 3 
μg/ml puromycin. 
 
3.2.3 3D cell-culture system 
Cells were cultured in DMEM/F-12 medium supplemented with 10% fetal bovine 
serum and 10% Matrigel (BD Biosciences, USA) and grown in Costar’s clear flat-bottom 
ultra-low-attachment plates (Corning, USA) to mimic the natural tissue environment. 
Fresh media were added into each culture well every 3 days. 
 
3.2.4 Reagents and chemicals 
Recombinant human CXCL8 and MIF proteins were obtained from R&D Systems 
(Cat. 208-IL-010 and 289-MF-002). CXCR2 inhibitor SB225002 (Cat. sc-202803A) and 
MIF antagonist ISO 1 (ab142140) were purchased from Santa Cruz Biotechnology and 
Abcam, respectively. Both CXCR2 and MIF were freshly dissolved in 10% DMSO for 
animal treatment experiments. For cell death staining experiments, 4,6-diamidino-2-
phenylindole (DAPI, D1306) and SYTOX Red dead-cell stain (Cat. S34859) were 
purchased from Thermo Fisher Scientific. 5-Bromo-2-deoxyuridine (BrdU), hyauronidase 
type IV-S (H3884-50 mg), hyauronidase I-S (H3506-500 mg), hyauronidase VIII (H3757-
100 mg) and propidium iodide (PI) were obtained from Sigma. Collagenase A (Cat. 
10103578001) was purchased from Roche.  
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3.2.5 BrdU incorporation and detection assay 
In vitro: 5 mg/ml BrdU stock solution was prepared by dissolving 5 mg of BrdU in 
1 ml sterilized phosphate-buffered saline (PBS, pH 7.4). 10 μl of BrdU stock solution was 
added into cell culture for 1 to 3 hours before cell fixation and permeabilization steps. In 
vivo: 10 mg/ml BrdU stock solution was prepared in sterilized PBS solution. Mice were 
given 1 mg BrdU through intraperitoneal (i.p.) injection for 3 times during 3 consecutive 
hours a day before tumor collection. Meanwhile, mice also fed with 1 mg/ml of BrdU water 
supplemented with 5% sucrose for 24 hours before tumor collection. Both in vitro and in 
vivo tumor cell BrdU staining and detection procedures were described previously.(239, 
240) 
 
3.2.6 Real-time PCR analyses 
Total RNA from cells was isolated with Trizol reagent (Life Technologies). cDNA 
was generated by an iScript cDNA Synthesis Kit (Bio-Rad) following the manufacturer’s 
protocol. mRNA expression levels of 14-3-3ζ, IL-8, CXCR2, MIF and IL-1β were 
determined by qRT-PCR using a KAPA PROBE Fast qPCR Kit (KAPA Biosystems) and 
TaqMan primers (Hs03044281_g1, Hs00174103_m1, Hs01891184_s1, Hs00236988_g1 
and Hs00174097_m1) and normalized to 18S rRNA endogenous control (#4310893E). 
 
3.2.7 Cell cycle analysis 
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Cells were harvested and fixed with ice-cold 70% ethanol at least 24 hours before 
cell cycle analysis. Every cell sample was washed twice with PBS to remove ethanol and 
incubated with 500 µl PI DNA staining solution (5 µl of a 100 µg/ml RNase stock, 50 µl of 
a 10 mg/ml bovine serum albumin stock, 25 µl of a 1 mg/ml propidium iodide (PI) stock 
and 420 µl ddH2O) for 1 hour protected from light. The PI signal, which represents 
different stages of the cell cycle, was measured by the Canto II FACS system (BD) and 
analyzed by FlowJo software. 
 
3.2.8 Annexin V staining and apoptosis assay 
Cells were harvested and washed twice with Phosphate buffered saline (PBS) before 
suspending with 100 µl of 1X binding buffer (Cat. 556454, BD Biosciences) containing 5 
µl of Pacific blue–labelled anti–Annexin V antibody and 1 µl of SYTOX Red dead-cell 
stain. Early and late apoptotic events were measured by flow cytometry system (BD) and 
analyzed by FlowJo software (http://www.flowjo.com/). 
  
3.2.9 Cytometric Bead Array (CBA) analyses 
The human inflammatory cytokine CBA kit (Cat. 551811, BD Biosciences) is a 
panel of six cytokines or chemokines for detection of protein expression levels in a sample. 
The required sample volume is about one-sixth of the volume used in conventional ELISA. 
Cell lysates or tumor fluids were first incubated with six-bead populations, which were 
coated with antibody specific for capture of IL-8, IL-1β, IL-6, IL-10, TNF and IL-12p70 
proteins. Samples were then washed, measured and analyzed following the 
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manufacturer’s instructions. The measurement and data analyses were done by a LSR II 
flow cytometry system and FCAP Array v3.0 Software (BD Biosciences). 
3.2.10 Gene expression profiling 
ζ-high, ζ-low and HET xenograft tumors were chopped into small pieces using 
blades and then transferred into a 15 ml tube to incubate with 3 ml digestion buffer at 
37 °C for 15 minutes to generate a single-cell suspension. Digestion buffer was made by 
cell recovery solution (Cat. 354253, Corning), Trypsin-EDTA (25200-056, Thermo Fisher 
Scientific) and DMEM/F12 medium with a 2:1:1 ratio and supplemented with 1 mg/ml 
hyaluronidase and 1 mg/ml collagenase A. The dead cells in single-cell suspension were 
removed by the Dead Cell Removal Kit (Miltenyi Biotec) according to the manufacturer’s 
instructions. FACS was then performed to sort out GFP+ (shCtrl) and TdR+ (shζ) cells 
from the live-cell fraction. Total RNA in GFP+ and TdR+ cells was extracted using a 
PureLink® RNA Mini Kit (Thermo Fisher Scientific). All RNA samples meet the quality 
criteria: OD260/280 ≥1.7, OD260/230 ≥1.5, RNA integrity number (RIN) ≥7 and 
concentration ≥33 ng/µL. Gene expression profiling of 12 samples was done on a 
HumanHT-12 v4 Expression BeadChip, which targets more than 47,000 probes (Illumina). 
 
3.2.11 ELISA  
Human IL-1β protein, human IL-8 protein and human active MIF protein were 
quantified by using ELISA kits (Cat. 447007, Cat. 431504, Cat. 438407; Biolegend) 
following the manufacturer’s protocol. 
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3.2.12 Human cytokine array 
35 µl of in vivo tumor fluids from HCC1954.shCtrl and HCC1954.shζ cells were 
assessed with human cytokine array panel A (Cat. ARY005, R&D Systems) following the 
manufacturer’s procedure. Each dot represents a specific protein expression, which was 
quantified by ImageJ software (https://imagej.nih.gov/ij/). 
 
3.2.13 Animal studies and drug treatment 
All mouse experiments were performed following protocols approved by MD 
Anderson’s institutional animal care and use committee. Tumor xenografts were 
established by injecting 1x106 HCC1954 subline cells in a 50 μl mixture of DMEM/F-12 
and Matrigel (BD Biosciences) with a 1:1 ratio orthotopically into the m.f.p. in SWISSnu/nu 
mice, which were obtained from the Department of Experimental Radiation Oncology at 
MD Anderson. Tumor volume (V) was measured weekly after transplantation, and 
calculated using the formula: V = length x (width)2/2 (200). To evaluate the potential 
therapeutic effect in mice, the dosage of ISO 1 (20 mg/kg) and SB225002 (2.5 mg/kg) 
were adjusted and followed studies described previously (241-243). To assess shCtrl-to-
shζ cell ratio in tumors, we processed tumor using the methods described in the section 
“Gene expression profiling” and analyzed the GFP+ to TdR+ cell ratio, which indicated 
shCtrl and shζ, respectively, by flow cytometry. 
 
3.2.14 Tissue specimens for 14-3-3ζ expression analysis 
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Tissue specimens including atypical ductal hyperplasia (ADH; 42 cases), DCIS (44 
cases), and invasive ductal carcinoma (48 cases) were collected and processed in 
compliance with protocols (LAB10-0995) approved by the IRBs of MD Anderson Cancer 
Center and Southern Medical University (China), which was described previously (154). 
Consent forms were obtained from all patients. IHC staining of 14-3-3ζ expression was 
performed following procedures described in the section “IHC analyses”. The percentage 
of 14-3-3ζ expression in every tissue slide was assessed and analyzed by a pathologist 
(Dr. Qingling Zhang MD). 
 
3.2.15 Antibodies 
We used the following antibodies for IHC staining and western blotting: anti–14-3-
3ζ, anti-MIF, and anti-GAPDH (clone C-19, clone FL-115 and clone G-9 respectively, 
Santa Cruz Biotechnology); anti–β-actin (Sigma); anti-BrdU (Abcam); anti–red 
fluorescent protein (tdRed) (Rockland); anti-GFP, anti–phospho-Akt, anti-Akt, anti–
phospho-c-Jun, anti–c-Jun, anti–cleaved caspase 3, anti–phospho-p38 MAPK 
(Thr180/Tyr182), anti–phospho-STAT1 (Tyr 701), anti-STAT1, and anti–c-IAP2 (catalog 
no. 2955, 4060, 2920, 3270, 9165, 9664, 4511, 9167, 14994 and 3130, respectively; Cell 
Signaling Technology); and anti–minichromosome maintenance 2 (MCM2) (clone EP40, 
Epitomics). For flow cytometry analyses, PE/Cy7- or APC-labelled anti–human CD182 
(CXCR2) antibody, PE/Cy7-labelled anti–human CD184 (CXCR4) antibody and APC-
labelled anti-BrdU antibody were purchased from BioLegend; Pacific blue–labelled anti–
Annexin V was purchased from Thermo Fisher Scientific. The optimal antibody dilutions 
for IHC is 1:100; for western blotting is 1:1000. 
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3.2.16. Immunoblotting  
Western blot samples including mouse xenograft tumors and cell lysates were 
prepared in RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton 
X-100, 0.1% SDS, 140 mM NaCl and 1x protease inhibitor). Immunoblotting was done as 
previously described (162) using antibodies listed in the “Antibodies” paragraph above. 
 
3.2.17 IHC analyses and tissue microarray (TMA) 
Mouse tumors were collected and embedded in paraffin following standard 
pathological procedures. Antigen retrieval and IHC analyses were performed as 
described previously (154). To achieve double IHC staining of proliferation marker BrdU 
or apoptotic marker cleaved caspase 3 together with staining for GFP and TdR 
expression, AEC substrate-chromogen (Dako) and DAB substrate-chromogen (Dako) 
were used following the manufacturer’s procedures. AEC substrate-chromogen stained 
as pink to indicate GFP or TdR expression; DAB substrate-chromogen stained as brown 
to indicate the expression levels of BrdU or cleaved caspase 3. Antibodies for IHC double 
staining were listed in the “Antibodies” paragraph above. To assess the clinical relevance, 
we stained 14-3-3ζ and CXCR2 in a 70-case, 208-core breast cancer tissue microarray 
(catalog no. BR2085a trial, US Biomax Inc.), which contained normal breast tissue and 
different grades of breast cancer tissues. The scores for staining power were identified 
by pathologist Dr. Qingling Zhang as 0, 1+, 2+, or 3+, with 3+ indicating higher expression 
and 0 indicating no expression. 
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3.2.18 Statistical analyses 
GraphPad Prism 6 and IBM SPSS Statistics 19 were used to analyze data. A 
Pearson’s correction was used to investigate whether the expression levels of 14-3-3ζ 
and CXCR2 are positively correlated. Differences between groups were assessed using 
the Student’s t test or ANOVA and were considered significant if P values were less than 
0.05. 
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3.3 Results 
3.3.1 Cells with higher 14-3-3ζ expression induce cell competition 
14-3-3ζ expression is associated with disease progression, metastasis and poor 
survival (157, 158). In breast cancer, 14-3-3ζ was overexpressed in pre-cancerous breast 
lesions and was persistently overexpressed throughout disease progression (158). To 
gain insight into the 14-3-3ζ expression pattern during breast cancer progression, I 
detected 14-3-3ζ expression by IHC staining of specimens of different stages of breast 
cancer. Fascinatingly, 14-3-3ζ expression was highly heterogeneous at early neoplastic 
stages such as atypical ductal hyperplasia (ADH) and DCIS (Figure 28A); however, as 
disease progressed into invasive ductal carcinoma (IDC), the 14-3-3ζ expression 
expanded to up to 100% of tumor cells (Figure 28B). This result suggests that 14-3-3ζ 
expression is favorably enriched and may benefit cell survival during tumor progression.  
To examine the oncogenic function of 14-3-3ζ in a relatively early stage of breast 
cancer, I knocked down 14-3-3ζ in HCC1954 cells (HCC1954.shζ), a cell line derived from 
stage IIA breast cancer (Figure 29A) (244, 245). HCC1954.shζ cells and vector control 
cells were labelled with red (TdR) and green fluorescence protein (GFP), respectively. To 
mimic the clinical scenario of heterogeneous cell types, I mixed 14-3-3ζ knockdown cells 
(shζ.TdR) and control cells (shCtrl.GFP) in a 1:1 ratio and orthotopically transplanted 
them into mouse mammary fat pads (m.f.p.) to form HET tumors (Figure 29B). Similar to 
what I observed in breast cancer patients, shCtrl.GFP cells always colonized the whole 
tumor population at the end stage of the tumorigenicity assay (Figure 29C). To avoid dye 
bias and to assess replicability of the study, a further dye-swap experiment was 
performed, and I observed an analogous phenomenon; again, 14-3-3ζ-high cells 
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(shCtrl.TdR) surpassed tumor populations at the late stage of the tumorigenicity assay 
(Figure 29C). In addition, there was no significant difference in terms of tumor growth 
between shCtrl (14-3-3ζ-high or “ζ-high”) and shζ (14-3-3ζ-low or “ζ-low”) tumors when 
they grew individually (Figure 29D). These data suggest that when shζ cells grew with 
shCtrl cells a distinct cell growth rate and cell death mechanism were induced in HET 
tumors.  
To investigate when the cell-ratio change occurred in HET tumors, I analyzed the 
shCtrl-to-shζ ratio through GFP-to-TdR signal ratio by flow cytometry every consecutive 
week after xenograft implantation. At week 5, the shCtrl-to-shζ ratio amplified to 2.8, and 
it gradually increased to 8 at week 8 (Figure 30A). Yet individually grown ζ-high and ζ-low 
tumors maintained a similar growth rate, even when I directly dissect the tumor growth 
rate into cell number level (Figure 29D). Next, further examined the weekly shCtrl-to-shζ 
ratio of cells freshly extracted from individually grown ζ-high and ζ-low tumors, the shCtrl-
to-shζ ratio maintained a ratio close to 1 throughout the assay (Figure 30A). These data 
suggest that when shCtrl and shζ cells grow together, the growth rate gradually changes 
in both cells. Intriguingly, I did not observe a significant difference in tumor size between 
HET tumors and individually grown ζ-high and ζ-low tumors (Figure 29D). The data 
indicate that shCtrl (14-3-3ζ-high) cells may induce cell death in shζ (14-3-3ζ-low) cells, 
thereby slowly changing the composition ratio of shCtrl and shζ cells in HET tumors. This 
cell competition mechanism seems to be preserved in the fly, in which integrity of tumor 
size was maintained under 14-3-3ζ variation (234). 
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Figure 28. 14-3-3ζ overexpression is selectively elevated during breast cancer 
progression. A, Representative IHC staining for 14-3-3ζ in specimens from patients with 
different stages of breast cancer. ADH: atypical hyperplasia, DCIS: ductal carcinoma in 
situ, IDC: invasive ductal carcinoma. B, Percentage of tissue containing 14-3-3ζ 
expression in specimens from different stages of breast neoplasia. ADH, n=42; DCIS, 
n=44; IDC, n=48. The data are in collaboration with Dr. Qingling Zhang.   
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Figure 29. 14-3-3ζ high breast cancer cells have growth advantages in a HET 
tumors. A, Upper, qRT-PCR analysis of relative 14-3-3ζ mRNA expression in HCC1954 
sublines was normalized by 18S rRNA expression. Bottom, western blotting of 14-3-3ζ 
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proteins in HCC1954 sublines. Schematic summary of individually grown ζ-high and ζ-
low tumors, as well as HET tumor. B, HET tumor contains ζ-high and ζ-low cells implanted 
in a 1:1 ratio into m.f.p. to form tumor xenografts with heterogeneous 14-3-3ζ expression. 
C, Images of late-stage tumors at week 8. Top panel, shCtrl (GFP+) mixed with shζ (TdR+) 
cells to form HET tumor; bottom panel, dye-swap experiment with shCtrl (TdR+) mixed 
with shζ (GFP+) to form HET tumor. D, The tumor volumes of shCtrl, shζ#1, shζ#2 and 
HET tumors were measured every week after xenograft implantation.  
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To demonstrate cell proliferation and apoptosis in shCtrl and shζ cells from HET 
tumors, I performed IHC double staining for a proliferation marker (bromodeoxyuridine, 
BrdU) and an apoptosis marker (cleaved caspase 3) along with GFP or TdR staining. I 
analyzed the percentage of proliferative and apoptotic events in shCtrl (GFP positive 
staining) and shζ cells (TdR positive staining) at different time points of tumor progression. 
From week 4 to 8, shCtrl cells showed an increase in proliferation compared to shζ cells 
(Figure 30B), whereas from week 6 to 8, shζ cells showed an increase in apoptosis 
compared to shCtrl cells (Figure 30C). However, there was no significant difference in 
terms of proliferation and apoptosis between shCtrl and shζ cells in their individually 
grown ζ-high and ζ-low tumors (Figure 30D and 30E). To further detect which stages of 
apoptosis in shζ cells was altered by shCtrl cells, I stained cells extracted from HET 
tumors with apoptotic markers (Annexin V and Sytox Red DNA dye). Interestingly, shζ 
cells had increased late-stage apoptotic cells compared to shCtrl cells in HET tumors 
(Figure 30F). To confirm the results of cell proliferation between shCtrl and shζ cells in 
HET tumors, I stained shCtrl and shζ cells with BrdU along with GFP and TdR and then 
quantified the percentage of co-localization signal. Indeed, similar to the results of the 
IHC double staining data (Figure 30B), cell proliferation was increased in shCtrl cells 
compared to shζ cells (Figure 30G). Taken together, the data indicate that 14-3-3ζ 
mediates cell competition by increasing cell proliferation in 14-3-3ζ-high cells (winner cells) 
while increasing cell apoptosis in 14-3-3ζ-low cells (loser cells). 14-3-3ζ-low cells were 
gradually eradicated by 14-3-3ζ-high cells, which then proliferate to fill the space and gap 
left by the disappearing loser cells (Figure 31). 
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Figure 30. 14-3-3ζ-high cells induce growth rate changes in HET tumors. A, shCtrl-to-shζ 
ratio was analyzed through the GFP-to-TdR signal ratio by flow cytometry. The individually grown 
shCtrl-to-shζ ratio reflects the ratio for ζ-high tumors together with that for ζ-low tumors; the HET 
tumor ratio indicates the ratio from HET tumors in which the two types of cells were implanted 
together. B-C, Consecutive HET tumor slides stained with proliferation marker BrdU (B) or 
apoptosis marker cleaved caspase 3 (C) along with GFP staining (shCtrl) or TdR staining (shζ). 
Quantification of the percentage of BrdU-positive or apoptosis marker (B) or cleaved caspase 3 
(C) IHC staining in shCtrl and shζ cells. D-E, IHC staining of proliferation marker BrdU-positive 
cells (D) and TUNEL-positive cells (E) in individually grown ζ-high (shCtrl) and ζ-low (shζ) tumors. 
F, Histograms show early and late apoptotic events in shCtrl and shζ cells extracted from ζ-high, 
ζ-low and HET tumors. G, Co-IF staining of BrdU marker and GFP or TdRed staining. Scale bar 
represents 50 μm. Error bars, S.D. *** indicates P<0.001 and * indicates P<0.05 by Student t-test. 
The data are in collaboration with Dr. Qingling Zhang   
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Figure 31. Schematic summary of how 14-3-3ζ mediates cell proliferation and 
apoptosis during cancer progression in HET tumors. When 14-3-3ζ-high cells grew 
with 14-3-3ζ-low cell in HET tumors, cell growth rate and cell death mechanism were 
changed in both cells. 14-3-3ζ-high cells (winner cells) increasing cell apoptosis in 14-3-
3ζ-low cells (loser cells) at the early stage of tumorigenesis assay. During tumor 
progression, 14-3-3ζ-low cells were gradually eradicated by 14-3-3ζ-high cells, which 
then proliferated to fill the space and gap left by the disappearing loser cells. Green: shCtrl 
cells (14-3-3ζ-high cells or winner cells); red: shζ cells (14-3-3ζ-low cells or loser cells). 
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3.3.2 Upregulation of IL-8 in 14-3-3ζ-high cells is critical to drive cell 
competition 
To dissect the molecular mechanism underlying the cell competition of the “winning” 
14-3-3ζ-high over the “losing” 14-3-3ζ-low cells in HET tumors, I performed an unbiased-
approach gene expression profiling analysis in shCtrl and shζ cells freshly extracted from 
HET tumors and individually grown ζ-high and ζ-low tumors. I noted the top hits that were 
upregulated in shCtrl cells versus shζ cells specifically in HET tumors. Remarkably, pro-
inflammatory ligands, IL-1β and IL-8, were significantly upregulated in shCtrl cells 
compared to shζ cells (Figure 32A). Meanwhile, I analyzed the top 10% of genes that 
were altered between the shCtrl and shζ cells through Ingenuity pathway analysis (IPA). 
Interestingly, IL-1β and IL-8 signaling ranked among other top altered pathways (Figure 
32B); the biological functions cell growth and cell survival were listed as the top two 
mechanisms (Figure 32C); revealed by IPA. These data suggest that 14-3-3ζ may 
modulate the pro-inflammatory pathway, thereby mediating cell competition. 
To validate the array profiling data, I used qRT-PCR to examine mRNA expression 
of IL-1β and IL-8 in shCtrl and shζ cells. shCtrl cells had an increase in mRNA expression 
of IL-8 and IL-1β compared to shζ cells (Figure 33A and 33B). Importantly, IL-8 
expression was upregulated only in shCtrl cells from HET tumors, but was only moderate 
effect in the shCtrl cells from individually grown ζ-high tumors (Figure 33B). To test protein 
expression of IL-8 and IL-1β in shCtrl and shζ cells, I performed cytometric bead array 
(CBA) analysis, which can measure multiple ligands, including IL-8 and IL-1β, with better 
sensitivity than traditional ELISA. In shCtrl cells, IL-8, IL-1β, IL-6 and IL-12p70 showed 
higher expression compared to shζ cells (Figure 33C). Among these inflammatory ligands, 
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IL-8 expression showed the highest increase in shCtrl cells compared to shζ cells (Figure 
33C and 33D), whereas it did not show a consistent expression pattern in cells from 
individually grown tumors (Figure 33D). I also tested IL-8 in secretion form in tumor fluids; 
IL-8 was increased 2-fold in HET tumor compared to ζ-high and ζ-low tumors (Figure 33E). 
Because inter-mouse heterogeneity affects basal cytokine expression levels, the 
significant upregulation of secretory IL-8 in HET tumors versus ζ-high and ζ-low tumors 
was only observed when these tumors were implanted into the same mouse. These data 
suggest that increased IL-8 expression in shCtrl cells contributed to secretory IL-8 in HET 
tumors, which may be relevant to cell competition. 
To investigate whether IL-8 is critical for 14-3-3ζ to mediate cell competition, I 
knocked down IL-8 in HCC1954.shCtrl (shCtrl.shIL-8) cells and implanted shCtrl.shIL-8 
cells together with shζ cells in a 1-to-1 ratio to establish HET.shIL-8 m.f.p. tumors. I first 
verified secretory IL-8 in tumor fluids; indeed, secretory IL-8 was significantly reduced in 
both HET.shIL-8 tumors and shCtrl.shIL-8 tumors (Figure 34A). To investigate whether 
IL-8 is sufficient to induce cell competition, I analyzed the shCtrl.shIL-8–to-shζ ratio in 
HET.shIL-8 tumors. Excitingly, knockdown of IL-8 significantly reduced the competition 
ratio that was altered by 14-3-3ζ (Figure 34B). Additionally, knockdown of IL-8 
significantly inhibited tumor growth in HET.shIL-8 tumors compared to vector control HET 
tumor (Figure 34C). These data indicate that upregulation of IL-8 is not only crucial for 
14-3-3ζ-mediated cell fitness but also facilitates tumor growth. 
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Figure 32. Gene expression profiling analysis in shCtrl and shζ cells from HET 
tumors. A, Four HET tumors were collected at weeks 8, 10, and 12. IL-8, IL-1β and MIF 
showed significantly altered between shCtrl and shζ cells from HET tumors. B, IPA 
ranking of the most altered cancer pathways from the top 10% of genes in terms of 
differing expression between shCtrl and shζ cells. IL-1 and IL-8 were in higher positions. 
C, IPA ranking of the most altered disease and biological functions from the top 10% 
genes in terms of differing expression between shCtrl and shζ cells. Cell growth and cell 
death rank among the top dysregulated biological functions.   
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Figure 33. Upregulation of IL-8 in 14-3-3ζ-high cells contributes to tumor growth. A-
B, qRT-PCR analysis of relative IL-1β (A) and IL-8 (B) mRNA expression in HCC1954 
sublines, normalized by 18S rRNA expression. C, CBA analysis showed that shCtrl and 
shζ have different levels of cytokine expression. Histograms showed that four ligands (IL-
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8, IL-1β, IL-6 and IL-10) were increased in shCtrl compared to shζ cells. Inset, among the 
four cytokines and chemokines, shCtrl cells (red) had a 3-fold increase in IL-8 expression 
compared to shζ cells (blue). D, CBA analyses revealed that ζ-high cells upregulated IL-
8 expression compared to ζ-low cells in HET tumor. E, CBA analyses showed that HET 
tumor increased secretory IL-8 compared to individually grown ζ-high and ζ-low tumors. 
F All bars, S.D. *** indicates P<0.001 and * indicates P<0.05 by Student t-test. 
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Figure 34. Upregulation of IL-8 in 14-3-3ζ high cell mediates cell competition. A, 
Knockdown of IL-8 significantly reduced secretory IL-8 in tumors, as shown by ELISA. B, 
Knockdown of IL-8 in shCtrl cells (shCtrl.shIL-8) significantly reduced cell competition, 
thereby decreasing the ζ-high to ζ-low ratio. HET.shIL-8 tumors indicate xenograft 
transplantation of shCtrl.shIL-8 cells together with shζ cells. C, Knockdown of IL-8 
inhibited tumor growth. All error bars, S.D. *** indicates P<0.001 by Student t-test.  
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3.3.3 MIF-CXCR2-IL-8 axis is required for 14-3-3ζ to induce cell fitness 
Several evidence showed that MIF induces IL-8 production through a heteromeric 
receptor complex (246, 247) and a functional MIF receptor complex includes CXCR2 and 
CXCR4, CD74 and/or other receptors (247, 248). I first analyzed CXCR2 expression in 
shCtrl and shζ cells and found CXCR2 expression was reduced in shζ cells compared to 
shCtrl cells (Figure 35A). Interestingly, certain evidence has showed that MIF is a pro-
inflammatory cytokine originally discovered to be secreted in the immune response (249), 
which can stimulate IL-8 production by competing with other canonical ligands for binding 
to the CXCR2 receptor (248). To examine the upstream signaling that mediates IL-8 
production in shCtrl cells in HET tumors, tumor fluids of ζ-high and ζ-low tumors were 
collected and analyzed with a human cytokine array. Among the cytokines, macrophage 
inhibitory factor (MIF) expression was higher in ζ-low tumors than in ζ-high tumors (Figure 
35B), which was also observed in the microarray profiling (Figure 32A). To validate the 
results from the cytokine array, I examined intracellular MIF expression in shCtrl and shζ 
cells and found that MIF was upregulated in shζ cells compared to shCtrl cells (Figure 
35C). In addition, MIF upregulation was observed in multiple 14-3-3ζ-knockdown cell lines, 
such as HCC70, Hs578T and BT-549 cells, compared to the corresponding control cells 
(Figure 35C). This finding suggests that MIF expression is modulated by 14-3-3ζ in breast 
cancer, where knockdown of 14-3-3ζ upregulates MIF expression. Interestingly, those 
data indicate that 14-3-3ζ modulates expression of cytokine MIF, and its own receptor 
CXCR2, which may affect survival-dependent pathway in cells.  
CXCR2 forms complexes with CD74 and other receptors, which are essential for 
mediating MIF-induced inflammation function (248). To test whether IL-8 expression was 
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induced by MIF through CXCR2 (Figure 35D), I stimulated shCtrl cells with human 
recombinant protein MIF and blocked it with CXCR2 antagonist SB225002. Upon MIF 
induction, both IL-8 mRNA expression and secretory IL-8 were upregulated in shCtrl cells, 
and this changed expression was further disrupted by SB225002 (Figure 35E). The data 
indicate that IL-8 production was directly modulated through the MIF-CXCR2 axis in 
shCtrl cells. This finding suggests that shCtrl upregulated IL-8 expression in HET tumors 
may be due to exposure to more MIF in the tumor environment. IL-8 expression primarily 
regulated by MIF-CXCR2 axis, blocking CXCR2 activation successfully inhibited IL-8 
production (Figure 35E). 
To determine whether targeting the MIF-CXCR2 axis inhibited cell fitness induced 
by 14-3-3ζ, I first established HET tumor xenografts in mouse m.f.p., and started to treat 
mice with MIF antagonist ISO 1 and CXCR2 antagonist SB225002 in the third week after 
implantation. I analyzed shCtrl-to-shζ cell ratio between the treatment and vehicle groups. 
Vehicle treatment moderately affected the shCtrl-to-shζ cell ratio (mean=3.64) compared 
to the non-treatment group (mean=8.1) (Figures 30A and 36A). Interestingly, the ISO 1- 
and SB225002-treated groups significantly reduced the shCtrl-to-shζ cell ratio (mean=1.9 
and 1.8, respectively) compared to the vehicle control group (mean=4.5) (Figure 36A). 
These data indicate that the impeding MIF-CXCR2 axis interrupted cell fitness induced 
by 14-3-3ζ in HET tumors. 
To determine whether disturbing MIF-CXCR2 affects cell proliferation and cell 
apoptosis in shCtrl and shζ cells, I analyzed apoptosis and proliferation in both types of 
cells extracted from HET tumors. Remarkably, blocking MIF in the HET tumor increased 
apoptosis in shCtrl cells but reduced apoptosis in shζ cells (Figure 36B). Moreover, 
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disrupting MIF binding reduced proliferation in shCtrl cells but increased proliferation in 
shζ cells (Figure 36C). However, inhibiting CXCR2 activation primarily had effects on 
apoptosis but not proliferation (Figure 36B and 36C). The data suggest that MIF-CXCR2 
signaling has distinct function in ζ-high (shCtrl) vs. ζ-low (shζ) expressing cells, whereas 
shζ cells are more dependent on the MIF-induced survival pathway. When shζ cells grew 
with shCtrl cells, shCtrl cells may compete with MIF from shζ that induce cell death in shζ 
cells.  
To examine whether 14-3-3ζ-high cells competed to sequester limited MIF ligands 
in HET tumors, thereby inducing cell competition, I analyzed the internalization rate 
between shCtrl and shζ cells. I found that 14-3-3ζ-high cells drive cell competition by 
successfully outcompeting 14-3-3ζ-low cells to internalize MIF in the tumor environment 
(Figure 36D), and removing MIF from 14-3-3ζ-low cells caused cell death. Our data 
indicate that 14-3-3ζ-high cells have extremely competitive capacity to eradicate 
subclones in genetically heterogeneous tumors through competing with survival signal. 
Hindering MIF-CXCR2 significantly reduced cell fitness and tumor growth caused by 14-
3-3ζ (Figure 36E). Thus, MIF and IL-8 are potential biomarkers for 14-3-3ζ-induced cell 
fitness in breast cancer. 
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Figure 35. MIF-CXCR2 axis is regulated by 14-3-3ζ. A, Flow cytometry analyses 
revealed that ζ-high cells have higher expression of CXCR2 compared to ζ-low cells. B, 
Top, cytokine array of tumor fluids (35 µl) from ζ-high and ζ-low tumors (short exposure). 
C, Western blotting of MIF and β-actin in multiple breast cancer sublines. D. Proposed 
model reveals MIF may induce IL-8 production through CXCR2. E, mRNA levels and 
protein levels of IL-8 expression as detected by qRT-PCR and ELISA, respectively, in ζ-
high cells (3D culture). All error bars, S.D. ** indicates P<0.01 by Student t-test.   
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Figure 36. MIF-CXCR2 axis mediates cell competition. A, Targeting HET tumors with 
MIF antagonist (ISO 1) or CXCR2 antagonist (SB225002) reduced the shCtrl-to-shζ ratio, 
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thereby inhibiting cell competition. B, Apoptosis was analyzed by Annexin V and SYTOX 
DNA dye, comparing MIF antagonist (ISO 1) and CXCR2 antagonist (SB225002) to 
vehicle control. C, Proliferation was affected by ISO 1 and CXCR2 inhibitor SB225002 
which as seen through regular PI cell cycle staining. D, MIF internalization rate between 
shCtrl and shζ cells. E, Tumor volume in the ISO 1- and SB225002-treated groups, as 
well as a vehicle (DMSO) control group. All error bars, S.D. ** indicates P<0.01 by Student 
t-test 
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3.3.4 The MIF-CXCR2 axis predicts worse clinical outcome 
Having established that the MIF-CXCR2 axis is potently regulated with regard to 
cell fitness and tumor growth by 14-3-3ζ breast cancer cells. Next, to assess whether 
each of MIF and IL-8 expression levels hold prognostic value for breast cancer, I then 
analyzed overall survival of the breast cancer dataset without subtype separation by an 
online Kaplan-Meier survival plotter (250). I found that high expression of MIF predicts 
poor survival of breast cancer patients (P=3.3e-08); high expression of IL-8 also predicts 
poor survival of breast cancer patients (P=0.00039) (Fig. 37A and 37B). These data 
suggest that inflammatory molecules MIF and IL-8 can predict worse clinical outcome in 
breast cancer. 14-3-3ζ mediated cell competition by regulating the inflammatory pathway, 
which increases the risk factors and is associated with shorter overall survival of breast 
cancer. 
       A       MIF   B             IL-8 
 
Figure 37. MIF-IL-8 axis proteins predict poor prognosis in breast cancer. A-B 
Kaplan-Meier overall survival curve of breast cancer patients. High expression of MIF (A) 
or IL-8 (B) was associated with poor overall survival (both log rank P<0.001).  
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3.4 Discussion 
Cell competition, a unique mechanism that orchestrates cell fate during 
development (251), has emerged as having a role in tumor suppression and has been 
proposed to be required for the progression from a pre-cancerous lesion to a tumor (235). 
I found that, in contrast to the traditional mechanism of loser-cell elimination is recognized 
by cell-cell interactions, 14-3-3ζ mediates cell competition through coordination of part of 
the inflammatory system and gradually removes unfit cells in tumor populations. The level 
of 14-3-3ζ determined the outcome of competitive races for tumor populations; cells with 
relatively higher 14-3-3ζ expression increased proliferation, reduced apoptosis and 
eliminated the slow-proliferating surrounding cells (14-3-3ζ-low cells). Mechanistically, 
14-3-3ζ-high cells outcompeted for survival ligand MIF via high expression of CXCR2 
(Figure 36D), thereby driving cell death in 14-3-3ζ-low-expressing cells in tumors with 
mosaic expression of 14-3-3ζ (Figure 38). Interestingly, because MIF showed distinct 
functions in 14-3-3ζ-high versus 14-3-3ζ-low cells during the cell competition, the 14-3-
3ζ-dependent MIF survival pathway becomes an Achilles heel and induce apoptosis in 
14-3-3ζ-low cells when MIF was sequestered out by 14-3-3ζ-high cells. In HET tumor, 14-
3-3ζ-high-expressing cells produce high levels of IL-8 through MIF-CXCR2 axis, which 
may further stimulate more IL-8 production as an autocrine signal, and contributes to cell 
fitness and tumor growth. 
A type of cell competition occurs in the “race” for dominance between mutant cells 
and wild-type cells (233); however, only a small number of genes such as Myc, which has 
been identified to transform cells into super-competitor when they are overexpressed in 
cells. In cancer, whether tumor-promoting protein 14-3-3ζ can induce cell to become 
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super-competitor, which needs further investigation in normal breast tissue. In the 
meantime, I have established a mammary gland-specific inducible 14-3-3ζ mouse (Figure 
39) that will allow further pursuit of these questions. Although it is unclear why the winner 
cells always require elimination of surrounding loser cells in order to proliferate, one 
explanation could be that loser cells may somehow restrain the growth capacity of winner 
cells through closely interacting with them (233). 
The classical cell death mechanism in loser cells—involving JNK-dependent 
apoptosis, intercalation of cells through regulation of F-actin, cell engulfment, and binding 
to diffusible death signal secreted by winner cells (166, 234, 252)—has been observed 
from flies to mammalian cells. Previously, in chronic lymphocytic leukemia B lymphocytes, 
MIF activated the CD74-NFkB pathway and resulted in activation of the IL-8-Bcl2 survival 
pathway (246). However, in the model, reduction of c-IAP2 expression (Figure 36F) may 
be the primary mechanism to increase cell apoptosis in shζ cells and presents a novel 
means of cell competition regulation through the c-IAP pathway besides the Bcl2 pathway. 
Meyer et al. reported that Myc induces cell competition by activating the innate 
immune system and triggering TRR-NF-κB-dependent apoptosis in the losing cells (253). 
In that model, winner and loser cells have distinct contexts, which are able to induce 
apoptosis in loser cells but not in winner cells. In the present study, 14-3-3ζ modulated 
expression levels of pro-inflammatory cytokines and their responding receptors. High 
endogenous 14-3-3ζ-expressing neoplastic clone upregulate CXCR2 expression on the 
cell surface, which efficiently creates more binding potential for ligands such as MIF in 
the tumor environment, which reduces the possibility of MIF-CXCR2 interaction in 14-3-
3ζ-low-expressing cells at the same time. Remarkably, I also observed that CXCR2 
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expression levels gradually increased over time in a tumorigenesis assay (Figure S4A), 
where shCtrl cells always had higher expression of CXCR2 levels compared to shζ cells. 
Whether MIF-induced IL-8 production has impacts on induction of CXCR2 expression 
could be further investigated. 14-3-3ζ-high cells exploited and repurposed the function of 
the MIF-CXCR2-IL-8 axis to enhance cell fitness. Activation of MIF-CXCR2-IL-8 in 
nonimmune cells could be potential diagnostic markers for cell competition in breast 
cancer. 
IL-8 signaling has been demonstrated to regulate invasion, migration and 
metastasis (254-256). During cell competition, endogenous higher-14-3-3ζ-expressing 
cells enhanced IL-8 signaling, which may be correlated to increased metastatic potential. 
In addition, upregulation of IL-8 was revealed to be an acquired therapeutic resistance 
mechanism in hepatocellular carcinoma (257). Chemotherapies, doxorubicin and 
paclitaxel, are commonly used for early-stage and advanced-stage breast cancer. 
Upregulation of IL-8 in 14-3-3ζ-high-expressing cells during breast cancer development 
may reduce drug sensitivity in patients who are receiving chemotherapy. The 
consequence of outcompeted cells in a heterogeneous tumor environment may enrich 
the potential to mediate therapy resistance and cancer metastasis. 
Since the current field does not have an efficient way to target 14-3-3ζ, blocking 
14-3-3ζ-high expressing cells with MIF or CXCR2 may be a potential therapeutic strategy 
to tackle tumor heterogeneity, cell fitness and potential metastasis or drug resistance. 
Altogether, my findings demonstrate that the MIF-CXCR2-IL-8 axis could be a critical cell 
competition feature in breast cancer and also show how cells gain advantages by 
efficiently acquiring extracellular ligands for cell proliferation and survival.  
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Figure 38. Proposed model of how 14-3-3ζ mediates cell competition and utilizes 
an inflammatory pathway. This schematic figure reveals how 14-3-3ζ modulates 
expression of cytokine and its own receptor, thereby changing cell context and survival-
dependent pathway. Cancer cells expressing different levels of 14-3-3ζ responded 
inversely upon macrophage inhibitory factor (MIF) stimulation, with 14-3-3ζ-low cells 
critically dependent on the MIF survival pathway. 14-3-3ζ-high-expressing cells can 
efficiently sequester MIF in a ligand-limited tumor environment via high expression of 
CXCR2, and reduction of MIF stimulation in 14-3-3ζ-low cells led to cell death and gradual 
elimination of the cells from tumors. In HET tumor, 14-3-3ζ-high-expressing cells produce 
high levels of IL-8 through MIF-CXCR2 axis. IL-8 may further stimulate more IL-8 
production by autocrine signal, which contributes to cell fitness and tumor growth. CXCR2 
may or may not couple with other receptors to effectively produce IL-8.  
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Chapter 4 
CONCLUDING REMARKS, FUTURE DIRECTIONS, AND 
PERSPECTIVES   
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4.1 Summary of findings 
 
This work began with the clinical observations that early identification and 
intervention can greatly increase the 5-year overall survival rate in breast cancer patients. 
There is an urgent demand to identify the mechanism driving breast cancer initiation in 
order to rapidly develop targeted prevention strategies to interfere with breast cancer 
development. Additionally, 14-3-3ζ expression was found to be greatly heterogeneous at 
the early neoplastic stage of breast cancer; as the disease progressed, the expression 
expanded to 100% of the tumor cells. The data suggest that the preferential accumulation 
of 14-3-3ζ during breast cancer development is critical for tumor growth and cell survival. 
However, it remains unclear how cancer cells obtain growth and cell fitness advantages 
through increasing expression levels of 14-3-3ζ during cancer progression. 
 
Metabolic alterations and cell competition during clonal selection are two important 
hallmarks of cancer. In this dissertation, I therefore pursued two major goals: first, to 
identify how 14-3-3ζ mediates metabolic alteration during early-stage breast cancer 
initiation (Chapter 2) and second, to examine how tumor cells selectively preserve high 
14-3-3ζ expression and how this may allow them to take over the tumor population by 
regulating their cellular fitness and benefiting cell survival and proliferation during cancer 
progression (Chapter 3). 
 
The research presented herein led to the discovery that the 14-3-3ζ expression 
level is strongly associated with the expressions of glycolytic genes in the pre-neoplastic 
and early malignant breast lesions, which persistently exist in the advanced stages of 
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clinical breast cancer (Figure 14, 15 and 16). Importantly, I has demonstrated that 14-3-
3ζ overexpression leads to increased glycolysis via upregulation of LDHA, facilitating 
breast cancer initiation and progression. Targeting 14-3-3ζ-overexpressing tumors with 
the MEK/ERK inhibitor AZD6244 can effectively inhibit mammary tumor growth 
(discussed in Chapter 2). 14-3-3ζ has distinct functions at the early and late stages of 
breast cancer. In addition, previous studies reported that context-dependent signaling 
defines the roles of protein in different stages of disease (258-260). When considered in 
the context of cancer, spanning from early stage to advanced stages and containing 
various genetic and non-genetic regulations, proteins cooperate with 14-3-3ζ in widely 
differing ways. Another encouraging finding on 14-3-3ζ’s role in cancer is that 14-3-3ζ 
exploits the inflammatory MIF-CXCR2-IL-8 axis, driving cell competition and eradicating 
the cells with lower 14-3-3ζ expression. This study led to the promising result that cancer 
is a disease caused by cell competition. Targeting mechanisms underlying cell 
competition may reduce 14-3-3ζ-mediated cell fitness and represent a potential 
therapeutic strategy to further inhibit tumor growth (discussed in Chapter 3). Collectively, 
my work suggests that the Warburg effect and MIF-CXCR2-IL-8 axis are novel 
therapeutic targets for the treatment of 14-3-3ζ-overexpressing breast lesions.  
 
A great deal of translational and clinical cancer research focuses on the 
development of biomarkers for earlier detection of cancer. Although modern technologies 
have allowed accurate diagnoses at relatively early stages of cancer, there remains a 
lack of promising biomarkers to result in a better prognostic assessment, especially 
without depending on a multi-marker testing strategy. Previous studies clearly showed 
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that the combination of multi-maker gene expression panels can lead to an accurate 
prognosis and better clinical decision making, but each gene expression panel may have 
limited specificity and sensitivity (261, 262). Indeed, the data in chapter 2 demonstrated 
that coexisting high expression of 14-3-3ζ and LDHA can be an efficacious prognostic 
biomarker in breast cancer, with more prediction power than either 14-3-3ζ or LDHA gene 
expression alone. My work has brought new insights into the molecular mechanism of 
early metabolic transformation, revealing that concurrent expression of 14-3-3ζ and LDHA 
could be applied into potential multi-marker panels for early intervention for breast cancer. 
 
Cancer is a sequential process of cell clonal selection and competition. During 
tumor progression, the fittest clonal population (winner population) with better growth 
abilities outcompetes other subclonal populations for the limited resources within a tumor. 
The cell competition mechanism garnered attention because it not only orchestrates cell 
fate during development (251), but is probably also required for the progression from a 
pre-cancerous lesion to a tumor (235). Understanding clonal evolution and dynamics of 
cell fitness may improve targeted therapy efficacy and enable efficient intervention in 
tumor progression. My work specifically identified that the 14-3-3ζ protein preferentially 
accumulates during breast cancer development, utilizes the inflammatory pathway for cell 
survival, and induces winner-induced cell death in breast cancer patients and xenograft 
tumors. Although I have observed that 14-3-3ζ-low cells have relatively lower glycolytic 
activity compared to 14-3-3ζ-high cells, the difference of metabolic rate doesn’t have 
significant impact on cell proliferation and cell competition. Interestingly, 14-3-3ζ can 
induce cell competition through 14-3-3ζ-mediated immune function. In cancers, 14-3-3ζ 
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overexpression enhances MAPK/c-Jun signaling (163), and regulates tumor immune 
response by modulation of multiple cytokines’ expression (164, 165). Interestingly, 14-3-
3ζ was found to directly interact with Stat3, which is essential for 14-3-3ζ-induced tumor 
inflammation. The evidence implicate that the role of 14-3-3ζ in tumor inflammation 
modulation and immune system. 
I demonstrated that cells expressing different levels of 14-3-3ζ responded inversely 
upon macrophage inhibitory factor (MIF) stimulation, with 14-3-3ζ-low cells critically 
dependent on the MIF survival pathway. 14-3-3ζ-high-expressing cells can efficiently 
sequester MIF in a ligand-limited tumor environment, and reduction of MIF stimulation in 
14-3-3ζ-low cells led to cell death and gradual elimination of the cells from tumors (Figure 
38). At the end stage of a tumorigenicity assay, 14-3-3ζ-high-expressing cells were 
always observed to colonize the whole tumor population, which is similar to what I 
observed in clinical breast cancer cases (Figure 28 and 29C). The level of 14-3-3ζ 
determined the outcome of competitive races within tumor populations; cells with 
relatively higher 14-3-3ζ expression increased proliferation, reduced apoptosis, and 
eliminated the slower-proliferating, 14-3-3ζ-low surrounding cells. Interestingly, 14-3-3ζ-
low cells can survive when they exist in a homotypic environment. But why should the 
winner clone (14-3-3ζ-high cells) always eliminate the loser clone (14-3-3ζ-low cells)? 
From a biological standpoint, it would make sense for the loser clone to be eliminated if it 
somehow restricted the growth of winner cells due to rivalry for limited resources in the 
tumor microenvironment. The exact feed-forward details were uncovered by utilizing 
inducible xenograft tumors to investigate the timing and biology of cell competition in vivo.  
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In present study, disturbing MIF-CXCR2 affects cell proliferation and cell apoptosis 
in shCtrl and shζ cells. Remarkably, blocking MIF in the HET tumor increased apoptosis 
in shCtrl cells but reduced apoptosis in shζ cells (Figure 36B). Moreover, disrupting MIF 
binding reduced proliferation in shCtrl cells but increased proliferation in shζ cells (Figure 
36C). The data suggest that MIF-CXCR2 signaling has distinct function in ζ-high (shCtrl) 
vs. ζ-low (shζ) expressing cells, whereas shζ cells are more dependent on the MIF-
induced survival pathway. When shζ cells grew with shCtrl cells, shCtrl cells may compete 
with limited MIF in the tumor environment from shζ cells, which induces cell death in shζ 
cells. Importantly, our data indicate that 14-3-3ζ-high cells have extremely competitive 
capacity to eradicate subclones in genetically heterogeneous tumors through competing 
with survival signal, MIF. 14-3-3ζ-high cells have higher CXCR2 expression compared to 
shζ cells. Hindering MIF-CXCR2 significantly reduced cell fitness and tumor growth 
caused by 14-3-3ζ (Figure 36E). Moreover, since IL-8 is increased in HET tumor 
compared to individually-grown tumors, I will further investigate whether IL-8 can serve 
as autocrine function to continuously maintain higher growth rate in shCtrl cells through 
binding to CXCR2. It is also important to further investigate whether IL-8 will compete wil 
MIF to bind to CXCR2. 
  
In the present study, I demonstrated a novel role of 14-3-3ζ in cell competition both 
in in vivo and ex vivo. Similar to what was observed in vivo, when shCtrl cells were grown 
with shζ cells, the shCtrl-to-shζ ratio increased, whereas the shCtrl-to-shζ ratio remained 
constant when these cells were grown individually. However, the degree of cell 
competition was slightly different between in vivo and in vitro results. The shCtrl-to-shζ 
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ratio in the co-culture system (in vitro) can only reach a maximum of 3:1 after long-term 
culture, while the shCtrl-to-shζ ratio in HET tumors (in vivo) gradually increased up to 8:1 
at late stage of tumorigenicity assay. These results suggest that the tumor 
microenvironment may further be involved in cell competition. One possible explanation 
is that increased IL-8 in the HET tumors may attract neutrophils to infiltrate into the tumor, 
and the neutrophils may accelerate the process of removing unfit cells within tumors, 
although this hypothesis merits further investigation. My work has added new weight to 
the generally accepted theory that cell competition may promote tumor progression. 
 
4.2 14-3-3ζ as a therapeutic target for cancer metabolism and tumor heterogeneity 
 
14-3-3ζ belongs to the highly conserved 14-3-3 scaffold protein family (157). 14-3-
3ζ has been reported to modulate numerous pathways and cellular functions in cancer 
such as invasion, apoptosis resistance, metastasis, chemotherapy resistance, and 
disease recurrence. Additionally, a heritable increase in 14-3-3ζ expression in cancer is 
associated with poor prognosis (158). Recently, 14-3-3ζ has been shown to be involved 
in numerous metabolic alterations (186), such as modulating the function of hypoxia-
inducible factor-1α (263), regulating adipogenesis (222), interacting with insulin signaling 
and facilitating glucose uptake (264), and binding to AMPK-target protein mTOR and 
coordinating cell growth (265). Furthermore, in cancer cells 14-3-3ζ physically interacts 
with phosphorylated LKB1 (192) and suppresses binding to and activation of its substrate, 
AMPK, a master sensor of cell metabolic flux, suggesting that 14-3-3ζ could be an 
important mediator of cellular metabolism. My work further demonstrated that 14-3-3ζ 
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overexpression is strongly correlated with the expression of glycolytic genes in breast 
cancer patients; and that 14-3-3ζ is a critical mediator of glycolysis, which may contribute 
to initiation, early transformation, and progression of breast cancer (Figure 27).  
 
Immune cells have been found to play an important role against cancer (266, 267). 
Certain studies showed that immune cells have distinct metabolic changes undergo 
activation of their immune functions while encountering danger signals (268). While tumor 
cells opt for metabolic reprograming like glycolysis to support rapid proliferation, evidence 
suggests that infiltrating immune cells such as tumor associated macrophages, T cells, 
and tumor infiltrating lymphocyte, also undergo similar glucose alterations. For example, 
during tumor progression, increased glycolysis in tumor associated macrophages would 
induce inflammation and increase inflammatory cytokines release, supporting tumor-
related inflammation. Activated effector T cell is marked by the by a switch from oxidative 
metabolism to glycolysis (71). Interestingly, cancer cells can compete for the limited 
glucose with tumor infiltrating lymphocyte in order to suppress the immune function in 
tumors (72, 73). Therefore, a better understanding of how metabolism fuels and 
modulates the maturation of immune responses may provide critical insights for cancer 
therapy (269, 270). 
 
Much evidence indicates that 14-3-3ζ may be a potential therapeutic target in 
cancer. Existing protein targeting approaches include the peptide inhibitor R18 (271), and 
nonpeptide inhibitor BV02 (272, 273) for inhibiting 14-3-3; both have been tested in vitro 
and BV02, which targets the protein-binding groove of 14-3-3, exhibited high efficacy 
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killing cells. Many lines of research are underway to identify the effect of pan-14-3-3 
inhibition in various diseases; yet, the development of a specific 14-3-3ζ inhibitor remains 
an urgent need in the field. Since there is currently no efficient way to target 14-3-3ζ, I 
may try to target 14-3-3ζ by interfering with its binding partners or downstream signaling 
pathways. In chapter 2, I have shown that inhibiting 14-3-3ζ-induced LDHA upregulation 
through targeting the 14-3-3ζ-downstream MEK/ERK pathway can effectively prevent the 
early-stage breast cancer progression in vivo by decreasing LDHA expression and 
reducing cell proliferation. In chapter 3, I have shown that inhibiting 14-3-3ζ-high-cell-
induced cell competition, both by blocking 14-3-3ζ-high cells with MIF antagonist ISO 1 
or CXCR2 antagonist SB225002, is explored as a potential therapeutic strategy to tackle 
tumor heterogeneity and cell fitness (Figure 34). Altogether, my findings help to provide 
novel therapeutic strategies to tackle 14-3-3ζ-overexpressing breast cancer, and are 
expected to provide new insights for translational research, perhaps even benefiting 
personalized medicine strategies to inhibit tumor growth.   
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4.3 Future directions 
 
Cancer is recognized as a disease of altered metabolism for almost 100 years, 
and metabolic alterations are currently identified as one of the important cancer hallmarks. 
Many drugs that directly target metabolic enzymes have been investigated in clinical trials 
(115) and targeting cancer metabolism has become a promising anti-cancer approach. 
However, because of the intra-and inter-tumor metabolic heterogeneity within and 
between tumors (274, 275), drugs that are directly targeted against metabolic enzymes 
have encountered several hurdles which will need to be overcome in the future. According 
to the results from clinical studies, no single-agent metabolic inhibitor alone is likely to 
successfully control tumor growth due to the extensiveness of tumor heterogeneity. There 
is a growing recognition that developing combinatorial therapies is critical to increasing 
treatment efficacy. In this dissertation, 14-3-3ζ overexpression-mediated LDHA 
upregulation contributes to aerobic glycolysis and early transformation in early-stage 
breast cancer. Targeting 14-3-3ζ/ERK/CREB/LDHA axis by using the 14-3-3ζ-
downstream pathway MEK/ERK inhibitor AZD6244 significantly inhibits tumor growth. 
The potent MEK/ERK inhibitor AZD6244 has also been used in combination with 
chemotherapies or other targeted therapies for treatment of advanced cancer (276), 
Consequently, AZD6244 may further combine with other agent such as an LDHA inhibitor 
in order to treat advanced breast cancer with overexpression of 14-3-3ζ. Several LDHA 
inhibitors have been developed and examined in preclinical and clinical studies such as 
FX-11 and AT-101 (181-183). I may further examine whether the combination of an LDHA 
inhibitor and MEK/ERK inhibitor AZD6244 has a synergistic effect for treating advanced 
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breast cancer. Another challenge in developing metabolism-targeted agents is that high 
dose-limiting toxicity frequently occurs in normal cells due to low specificity of metabolic 
enzyme activity for cancerous tissues. Although metabolic enzyme functions significantly 
impact tumorigenesis, on the other hand, they also conduct general physiological and 
signal transduction functions in normal cells throughout the body. The therapeutic window 
for cancer-targeted metabolic therapy may be too narrow for systemic administration, 
which can causes severe toxicity in patients. Synergistic combination strategies by using 
metabolic inhibitor(s) together with another first-line cancer drug may not only improve 
efficacy compared to single agent therapy, but also decrease drug toxicity by reducing 
the requisite drug dosage. Therefore, I will further investigate whether the combination of 
MEK/ERK inhibitor AZD6422 and an LDHA inhibitor can effectively inhibit the growth of 
14-3-3ζ-overexpressing tumors. 
 
Transgenic, gene knock-out, and gene knock-in mice are valuable models for 
studying human disease (277, 278). Inducible mouse models have been developed to 
overexpress and/or knock-out gene expression in order to investigate tumor biology at 
the desired time or stage of tumor development (279, 280). I have identified that increased 
expression of 14-3-3ζ in normal mammary epithelial cells leads to metabolic dysregulation, 
promotes mammary tumor initiation, triggers cell competition, and promotes breast 
cancer progression. To further investigate the role of 14-3-3ζ-mediated metabolic 
alteration in mammary gland development, mammary tumor initiation, and mammary 
tumor progression in vivo, use of transgenic mice with inducible mammary gland-specific 
14-3-3ζ overexpression will be valuable for studying how 14-3-3ζ is involved in metabolic 
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dysregulation and tumorigenesis in vivo. Importantly, two previous lab members, Dr. 
Qingfei Wang and Dr. Jun Yang, have cloned a 14-3-3ζ PCR product with human 
influenza hemagglutinin (HA) tag into bidirectional inducible pBI-L vector for pronuclear 
injection and generation of transgenic mice. With the help of the genetically engineered 
mouse facility (GEM) at University of Texas MD Anderson Cancer Center, Tet-HA-14-3-
3ζ mice have been successfully generated in a Friend virus b-type mice NIH Jackson 
(FVB/NJ) background. Tet-HA-14-3-3ζ mice were further crossed with a mouse strain 
whose mammary glands specifically and consistently express tetracycline-controlled 
transcriptional activation protein (rtTA) (mouse strain was given from Dr. Lewis Chodosh), 
to established mammary gland-specific, doxycycline-inducible 14-3-3ζ-expressing mice 
(MTB/T-HA-14-3-3ζ) (Figure 39A). The western blot (Figure 39B) and 
immunofluorescence (Figure 39C), results showed that upon doxycycline induction, 
inducible gene expression is tightly regulated and encodes HA-14-3-3ζ in mammary 
epithelial cells in the MTB/T-HA-14-3-3ζ mouse model, which can be used to examine the 
impact of 14-3-3ζ overexpression on cell metabolism and transformation (Figure 39). 
 
 My work has demonstrated that the 14-3-3ζ expression level is significantly 
correlated with the expression of glycolytic enzymes in pre-malignant and cancerous 
lesions. The MTB/T-HA-14-3-3ζ mouse model will serve as a valuable resource for 
investigating the significance of 14-3-3ζ and other glycolytic proteins, especially those 
that have been reported to be potential 14-3-3ζ partners including enzymes that are 
central to glycolysis such as pyruvate kinase (PK), glyceraldehyde-3-phosphate 
dehydrogenase (GADPH) and 6-phosphofructo-2-kinase (PFK-2) (191).  
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Lastly, in my present study, I found that the percentage of 14-3-3ζ expression was 
highly heterogeneous in early-stage breast cancer. However, when the breast cancer 
progressed into advanced stages, the percentage of 14-3-3ζ expression increased to 
almost 100% of breast lesions. Besides simply outcompeting the loser cells (14-3-3ζ-low 
cells) for limited resources in the tumor environment, it is important to understand whether 
there are other reasons why winner cells (14-3-3ζ-high cells) are positively selected 
during clonal evolution. During cell competition, endogenously high-14-3-3ζ-expressing 
cells enhanced IL-8 signaling, which was found to be able to drive cell competition. IL-8 
signaling has been demonstrated to regulate invasion and metastasis (254-256). In 
addition, upregulation of IL-8 was revealed to be an acquired therapeutic resistance 
mechanism in cancer (257). Chemotherapies are commonly used to treat for early-stage 
and advanced-stage breast cancer patients. Elevated IL-8 expression in winner cells (14-
3-3ζ-high cells) during the cell competition process may reduce drug sensitivity in patients 
who are receiving chemotherapy. Rather than simply select for cells with better 
proliferative capabilities, the consequence of cell competition in a heterogeneous tumor 
environment may be enriched potential to mediate therapy resistance and cancer 
metastasis. Therefore, an extended study to examine whether 14-3-3ζ-induced cell 
competition can further impact therapeutic resistance or metastasis is urgently needed. 
Altogether, my work demonstrates that the MIF-CXCR2-IL-8 axis may be a critical feature 
of cell competition. Ideally, in the future, I can further investigate whether MIF-CXCR2-IL-
8 axis can be biomarkers for cell competition in cancer. Recently, a great deal of focus 
has shifted to the field of immuno-oncology because immunological checkpoint blockade 
and adoptive cell transfer have showed impressive response rates in cancer patients. My 
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work demonstrated that 14-3-3ζ utilizes an immune pathway to induce cell competition in 
solid cancer, a setting that has not thus far benefited from major gains in immmuno-
oncology. Remarkably, blocking 14-3-3ζ-induced cell competition with MIF or CXCR2 
antagonists can reduce tumor growth and cell fitness, which may be a potential 
therapeutic strategy to tackle tumor heterogeneity and cell fitness, potentially extending 
the survival benefits seen with immunotherapy for melanoma and cancers of the blood 
into solid cancers. 
In summary, this work has discovered the two distinct roles of 14-3-3ζ in cancer 
metabolism and cell competition, and suggests two potential therapeutic strategies to 
tackle breast cancer initiation and progression. 
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Figure 39. Tet-inducible MTB/T-HA14-3-3ζ bitransgenic mouse model. A, Mice were 
administrated doxycyclin (Dox) at 1 and 2mg/mL in drinking water for 3d and measured 
under IVIS bioluminescence imaging system. It shows gene expression in the MTB/T-
HA14-3-3ζ is dox-dose-dependent indicating it can be induced at desired levels and 
desired time points. B, Western blot showed that inducible HA-14-3-3ζ only expressed in 
mammary glands (MFPl1, MFPl4 and MFPr1) whereas other organs such as liver and 
spleen have no inducible HA-14-3-3ζ signal. C, Immunofluorescence staining showed 
that the anti-HA specific signals co-localized with the anti-14-3-3ζ signals that further 
confirmed the histological staining results. 
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